US20220362344A1 - Treatment for sars-cov-2 and other coronaviruses - Google Patents
Treatment for sars-cov-2 and other coronaviruses Download PDFInfo
- Publication number
- US20220362344A1 US20220362344A1 US17/866,530 US202217866530A US2022362344A1 US 20220362344 A1 US20220362344 A1 US 20220362344A1 US 202217866530 A US202217866530 A US 202217866530A US 2022362344 A1 US2022362344 A1 US 2022362344A1
- Authority
- US
- United States
- Prior art keywords
- nps
- natriuretic peptide
- complication
- failure
- ace2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title abstract description 49
- 241000711573 Coronaviridae Species 0.000 title abstract description 4
- 108020001621 Natriuretic Peptide Proteins 0.000 claims abstract description 186
- 102000004571 Natriuretic peptide Human genes 0.000 claims abstract description 186
- 239000000692 natriuretic peptide Substances 0.000 claims abstract description 185
- 239000002792 enkephalinase inhibitor Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 21
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- YZEJNKFJIYNYMP-MGAVOHMASA-N (3S)-3-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN YZEJNKFJIYNYMP-MGAVOHMASA-N 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 50
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 45
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims description 42
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 35
- 102000005962 receptors Human genes 0.000 claims description 31
- 108020003175 receptors Proteins 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 25
- 230000001965 increasing effect Effects 0.000 claims description 24
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims description 21
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 21
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 18
- 230000015271 coagulation Effects 0.000 claims description 18
- 238000005345 coagulation Methods 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 230000002889 sympathetic effect Effects 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 15
- 206010021143 Hypoxia Diseases 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 206010047139 Vasoconstriction Diseases 0.000 claims description 13
- 210000002540 macrophage Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000037361 pathway Effects 0.000 claims description 13
- 230000025033 vasoconstriction Effects 0.000 claims description 13
- 206010050685 Cytokine storm Diseases 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 12
- 230000007954 hypoxia Effects 0.000 claims description 12
- 230000000770 proinflammatory effect Effects 0.000 claims description 11
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 11
- 230000000747 cardiac effect Effects 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 10
- 230000002222 downregulating effect Effects 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 6
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 6
- -1 iL2 Proteins 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 230000000241 respiratory effect Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 5
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000001276 controlling effect Effects 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 5
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 230000007115 recruitment Effects 0.000 claims description 4
- 210000004994 reproductive system Anatomy 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 101710091439 Major capsid protein 1 Proteins 0.000 claims description 3
- 108010035766 P-Selectin Proteins 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 3
- 208000015294 blood coagulation disease Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 claims description 3
- 238000007634 remodeling Methods 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 210000003038 endothelium Anatomy 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 210000005166 vasculature Anatomy 0.000 claims description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 3
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 claims 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 claims 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 102000042838 JAK family Human genes 0.000 claims 1
- 108091082332 JAK family Proteins 0.000 claims 1
- 102000008212 P-Selectin Human genes 0.000 claims 1
- 102100028748 Transportin-1 Human genes 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000008753 endothelial function Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 54
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 52
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 52
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 52
- 102100031478 C-type natriuretic peptide Human genes 0.000 description 42
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 39
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 39
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 38
- 208000025721 COVID-19 Diseases 0.000 description 35
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 32
- 102000003729 Neprilysin Human genes 0.000 description 30
- 108090000028 Neprilysin Proteins 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 30
- 230000036454 renin-angiotensin system Effects 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 description 24
- 229960003953 sacubitril Drugs 0.000 description 22
- 241000700605 Viruses Species 0.000 description 21
- 238000001990 intravenous administration Methods 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 230000007423 decrease Effects 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000028993 immune response Effects 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 206010019280 Heart failures Diseases 0.000 description 13
- 208000036142 Viral infection Diseases 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 11
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 10
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000024883 vasodilation Effects 0.000 description 10
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 229950006323 angiotensin ii Drugs 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 238000002483 medication Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
- 102400000345 Angiotensin-2 Human genes 0.000 description 8
- 101800000733 Angiotensin-2 Proteins 0.000 description 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 8
- 241001678559 COVID-19 virus Species 0.000 description 8
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000008482 dysregulation Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 8
- 229960004699 valsartan Drugs 0.000 description 8
- 102400000967 Bradykinin Human genes 0.000 description 7
- 101800004538 Bradykinin Proteins 0.000 description 7
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 6
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 102400001279 Urodilatin Human genes 0.000 description 6
- 230000007012 clinical effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 102000027424 natriuretic peptide receptors Human genes 0.000 description 6
- 108091008599 natriuretic peptide receptors Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- DOBNVUFHFMVMDB-BEFAXECRSA-N (2r,4s)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid Chemical compound C1=CC(C[C@H](C[C@@H](C)C(O)=O)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 DOBNVUFHFMVMDB-BEFAXECRSA-N 0.000 description 5
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 5
- 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 206010025327 Lymphopenia Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 5
- 206010047141 Vasodilatation Diseases 0.000 description 5
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007775 late Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 231100001023 lymphopenia Toxicity 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- 101710102157 Atrial natriuretic peptide receptor 3 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102400000321 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 206010020608 Hypercoagulation Diseases 0.000 description 4
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 4
- 102100036836 Natriuretic peptides B Human genes 0.000 description 4
- 101710187802 Natriuretic peptides B Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 102400000050 Oxytocin Human genes 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 108010001957 Ularitide Proteins 0.000 description 4
- 206010069351 acute lung injury Diseases 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 108010005565 anaritide Proteins 0.000 description 4
- PBSXKCQOTWYLMQ-LWECRCKRSA-N anaritide Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 PBSXKCQOTWYLMQ-LWECRCKRSA-N 0.000 description 4
- 229950004772 anaritide Drugs 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 108010038640 atrial natriuretic factor receptor A Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 230000003027 hypercoagulation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000009424 thromboembolic effect Effects 0.000 description 4
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
- 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 3
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 3
- 108010092674 Enkephalins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 229960002478 aldosterone Drugs 0.000 description 3
- 208000008445 altitude sickness Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229950008486 carperitide Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 108010082861 cyclic GMP-binding protein Proteins 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000010503 organ complication Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940100334 sacubitril / valsartan Drugs 0.000 description 3
- 229950007981 sacubitrilat Drugs 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 230000000476 thermogenic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 2
- 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 description 2
- 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 description 2
- 102000010183 Bradykinin receptor Human genes 0.000 description 2
- 108050001736 Bradykinin receptor Proteins 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- IRRLKLXYIZBPPF-YTGPIHSWSA-N CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O IRRLKLXYIZBPPF-YTGPIHSWSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000010445 Chilblains Diseases 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 101710134516 Des-Arg9-bradykinin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 101800001586 Ghrelin Proteins 0.000 description 2
- 102400000442 Ghrelin-28 Human genes 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 2
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- 101000841259 Homo sapiens Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 108010003195 Kallidin Proteins 0.000 description 2
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 108050004622 Membrane metallo-endopeptidase-like 1 Proteins 0.000 description 2
- 102100024197 Membrane metallo-endopeptidase-like 1 Human genes 0.000 description 2
- 102000003843 Metalloendopeptidases Human genes 0.000 description 2
- 108090000131 Metalloendopeptidases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 208000031709 Skin Manifestations Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- VCEHWDBVPZFHAG-POFDKVPJSA-N [des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-POFDKVPJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 101150054399 ace2 gene Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 108010021281 angiotensin I (1-7) Proteins 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000001054 cardiac fibroblast Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 108010029849 cenderitide Proteins 0.000 description 2
- 229950005717 cenderitide Drugs 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001517 counterregulatory effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 2
- 102000056614 human NPPA Human genes 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005980 lung dysfunction Effects 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 230000003818 metabolic dysfunction Effects 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 230000001452 natriuretic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 1
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- MZCACYLMMMXSKC-UHFFFAOYSA-N 32 amino acid peptide Chemical compound C=1C=CC=CC=1CC(C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C1N(CCC1)C(=O)C1NCCC1)C(C)O)CC1=CC=CC=C1 MZCACYLMMMXSKC-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 101100329003 Arabidopsis thaliana COV1 gene Proteins 0.000 description 1
- 101100456008 Arabidopsis thaliana MANP gene Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 241000320892 Clerodendrum phlomidis Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000270311 Crocodylus niloticus Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 241000272093 Dendroaspis Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000003965 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 229940122586 Enkephalinase inhibitor Drugs 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010013990 Guanylate Cyclase-Coupled Receptors Proteins 0.000 description 1
- 102000017178 Guanylate Cyclase-Coupled Receptors Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101100323220 Homo sapiens NPPA gene Proteins 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020989 Hypogeusia Diseases 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 1
- 101710187800 Natriuretic peptides A Proteins 0.000 description 1
- 102100034296 Natriuretic peptides A Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 description 1
- 206010071066 Posterior reversible encephalopathy syndrome Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 101000992426 Severe acute respiratory syndrome coronavirus 2 ORF9b protein Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102400000159 Thymopoietin Human genes 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229940104697 arixtra Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 108010038664 atrial natriuretic factor receptor B Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 229950009568 bemcentinib Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 1
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 description 1
- 229950004548 candoxatril Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- ODUOJXZPIYUATO-LJQANCHMSA-N ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 description 1
- 229950001184 ecadotril Drugs 0.000 description 1
- 230000000432 effect on mutation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940100321 entresto Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 235000019570 hypogeusia Nutrition 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JSOQIZDOEIKRLY-UHFFFAOYSA-N n-propylnitrous amide Chemical compound CCCNN=O JSOQIZDOEIKRLY-UHFFFAOYSA-N 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 108700040249 racecadotril Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229950009436 ularitide Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940100375 valsartan 103 mg Drugs 0.000 description 1
- 229940102035 valsartan 160 mg Drugs 0.000 description 1
- 229940100342 valsartan 26 mg Drugs 0.000 description 1
- 229940079292 valsartan 40 mg Drugs 0.000 description 1
- 229940100312 valsartan 51 mg Drugs 0.000 description 1
- 229940102034 valsartan 80 mg Drugs 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to methods and compositions for the treatment or prevention of SARS-CoV-2 (COVID-19) independent on the mutation, and other corona virus such as but not only, MERS, COV1, and other RNA and DNA viruses.
- SARS-CoV-2 COVID-19
- other corona virus such as but not only, MERS, COV1, and other RNA and DNA viruses.
- SARS-CoV-2 and other corona viruses are RNA viruses that infect living cells to reproduce.
- the virus enters the cell, replicates inside the cell, kills the cell, releases and infect other cells, creates a severe immune response cytokine storm, hypercoagulation, hypoxia, organ complications and death.
- RNA viruses have high mutation rates both random and adaptive—up to a million times higher than their hosts - and these high rates are correlated with enhanced virulence and evolvability, ultimately lead to escape from our current therapeutic and prophylactic interventions.
- the angiotensin-converting enzyme 2 (ACE2) receptor is present in humans and other species, which may explain the cross-species transmission.
- the ACE2 receptor is highly expressed in all organs but mostly in the lungs, nasopharynx, liver, pancreas, kidney, cardiovascular system, central nervous systems, and digestive system.
- SARS-CoV-2 virus The outer membrane of the SARS-CoV-2 virus is speckled with spiky proteins, which act as an anchor to the cell's ACE2 receptor.
- SARS-CoV entry-activating proteases include cell surface protease transmembrane serine proteases TMPRSS2 and HAT and lysosomal proteases cathepsins and ADAM17. Moreover, its cell entry is preactivated by proprotein convertase Furin, reducing its dependence on target cell proteases for entry.
- the critical step in any viral infection involves penetration of the viral particles into the cytosol; to this end, most viruses take advantage of the endocytic membrane trafficking of the host cell.
- the pattern recognition receptors which are proteins expressed mainly, by cells of the innate immune system, such as dendritic cells, macrophages, monocytes, and neutrophils, are activated, and trigger the secretion of cytokines.
- type 1/111 interferons IFNs
- IFNs type 1/111 interferons
- TNF-a proinflammatory tumor necrosis factor alpha
- IL-1 interleukin-1
- IL-18 interleukin-18
- SARS-CoV-2 proteins such as ORF9b
- IFN-I interferon pathway
- the SARS-COV-2 spike protein binds very efficiently with the ACE2 receptor causing it to become ‘downregulated’ and nonfunctional by cleaving from its ‘transmembrane domain’, ‘shedding’ of the extracellular portion which makes the ACE2 receptor to be ‘nonfunctional’ and unable to perform its normal functions.
- the downregulation of the ACE2 receptors leads to an increase in ACE and Ang II in the RAAS. This is critical because the ACE/Ang II/AT1 R axis plays an important role in promoting inflammation, vasoconstriction, hyper-coagulopathy and tissue damage, which contributes to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) and other organ failure which are the most serious complications of SARS-COV-2 and COVID-19.
- ALI Acute Lung Injury
- ARDS Acute Respiratory Distress Syndrome
- the disequilibrium from a healthy state in essential pathways and systems is probably the root cause of many COVID-19 morbidities.
- the above mechanism is in the root of the broader deranged systems. This includes the dysregulation of the Renin-Angiotensin-Aldosterone System (RAAS) and other axes that interact, and ‘cross talk,’ with the RAAS and each other.
- RAAS Renin-Angiotensin-Aldosterone System
- These cross-talking axes include the Kinin-Kallikrein System (KKS), the immune system, the sympathetic and parasympathetic systems, the reactive oxygen species (ROS) and the coagulation pathways.
- KS Kinin-Kallikrein System
- ROS reactive oxygen species
- COVID-19′s dysregulation of the RAAS produces an imbalance between its two axes: the ‘ACE/Angiotensin II/AT1R’ axis and the ‘ACE2/Angiotensin (1-7)/MAS’ axis.
- KKS Kinin-Kallikrein System
- BK Bradykinin
- KO kallidin
- the KKS interacts with the RAAS, and imbalances in one system can affect the other system and lead to serious complications.
- Kallikreins are responsible for regulating blood pressure, activating inflammation and vasodilatation as well as fibrinolysis.
- the RAAS interacts with the KKS by the ACE which is (also known as Kininase II) which deactivates mainly the bradykinin and by ACE2 that decrease the activity of the des-Arg9 bradykinin/BKB1R axis, which results in the release of pro-inflammatory chemokines. (REFERENCE 1).
- ROS Reactive Oxygen Species
- Oxidative stress originally described as an altered balance between the production of free radicals and antioxidant defenses, is an important phenomenon in different physiological and pathological processes.
- Several enzymes including xanthine oxidase, cytochrome P450 monooxygenase, the cyclooxygenase pathway of arachidonic acid metabolism, the plasma membrane NADPH oxidases, and in particular the components of the mitochondrial respiratory chain participate in oxidative stress.
- ROS superoxide anion
- hydroxyl radical hydroxyl radical
- H2O2 hydrogen peroxide
- the viral infection triggers a first response by the body's Innate Immune system.
- the dysregulation of the interferon IFN-1 plays a major role in the virulence of SARS-COV-2. (REFERENCE 14).
- the infected cells release ‘immune mediators’, cytokines and chemokines, which when in excess, cause severe inflammation.
- cytokines include Pro-inflammatory Cytokines: the interleukin IL-1 and Tumor Necrosis Factors (TNF); Type 1 Cytokines such as TNFa and the Interferon IFN-y; and Type2 Cytokines such as: the interleukins IL-4, IL-10, and IL-13, and the Transforming Growth Factor (TGF).
- TNF Tumor Necrosis Factors
- Type 1 Cytokines such as TNFa and the Interferon IFN-y
- Type2 Cytokines such as: the interleukins IL-4, IL-10, and IL-13, and the Transforming Growth Factor (TGF).
- TGF Transforming Growth Factor
- T cells are also heavily involved in the process.
- the T cell response is seriously affected by an overall reduction of CD4+ and CDS+ T cells, with short- and long-term severe effect.
- the SARS-COV-2 virus is infecting and destroying the T cells and decreasing the CD4+ and CDS+T cells. with lymphopenia eventually reaching ‘lymphocyte exhaustion,’ which increases the risk of serious secondary infections.
- the SARS-COV-2/COVID-19 disease progresses through four clinical phases with:
- the incubation period ranges from 1-21 days on the average.
- the main access by the virus is through the upper respiratory tract, nasopharynx, and mucosal secretions through the eyes and nose, as well as the gastrointestinal systems through the feces (‘fecal oral’ transmission).
- This stage is characterized by lungs involvement, with viral pneumonia, cough, fever, and possibly hypoxia, in different degrees, from mild to severe.
- cytokines such as, IL-2, IL-6, IL-7, granulocyte-colony stimulating factor (GCSF), macrophage inflammatory protein 1-alpha, TNF alpha, CRP, ferritin, and D-dimer, as well as elevated troponin and Brain Natriuretic Peptide (BNP) with several clinical complications including hypoxia, due to lung inflammation and infection, due to the ACE2 shedding, the overexpressed ACE/Angiotensin II, under expressed ACE2, the viral and secondary infection, as well as decreased shunt due to vasoconstriction. Also, other main organs malfunction which contributes to the hypoxia—the Central Nervous System (CNS) with dysregulation of the respiratory regulatory centers, due to the same driving forces, kidney, and heart failure.
- CNS Central Nervous System
- DIC micro-thromboembolism in the brain and other organs, and in small blood vessels throughout the body. This is caused by the dysregulation of the RAAS and imbalances between ACE and ACE2 and their counter-regulating axes, the dysregulated KKS and bradykinin systems, the systemic inflammation, the vasculature inflammation, and constriction.
- the deterioration and dysfunction of the essential systems makes organ complications inevitable and may also lead to death. Including lungs, cardiac, kidney, liver, central nervous system, coagulation decompensation with thromboembolic and DIC, immune system decompensation, including CD4+ and CDS+ immune cell deficiency, rhabdomyolysis and myositis, post infection and chronic fatigue syndrome.
- the complications may include also:
- this virus is traveling in a direction that could ultimately lead to escape from our current therapeutic and prophylactic interventions.
- the invention is of novel methods and compositions for treating subjects with SARS-COV-2 infection (COVID-19) and related viral infections, diseases, and conditions.
- SARS-COV-2 and/or “COVID-19” are intended to refer not only to SARS-COV-2 and COVID-19 but also to mutations/variants thereof.
- mutations/variants include: B.1.1.7 (a.k.a. 201/501 Y.V1); 69/70 deletion; P681 H; the South African variant, known as B.1.351 lineage (a.k.a. 20H/501 Y.V2); Manaus variant; the Brazilian variant; P.1 variant; and P.1 lineage.
- COVID-19 is a disease of imbalanced systems and the complications that result from the interaction of these imbalances, and that an effective treatment/composition for this disease must address these imbalances and complications as a system, for all stages of the disease and for a wide range of subjects.
- This invention is based on the insight that SARS-COV-2 infection, COVID-19, and related diseases cause a cascade of critical intertwined systemic pathway imbalances causing serious complications that can seriously impact the patient's health.
- NPs Natriuretic Peptides
- A-type NP A-type NP (ANP), B-type NP (BNP), C-type NP (CNP), D-type NP (DNP), Urodilatin and VNP (ventricular NP).
- NPs specifically, proBNP and BNP
- proBNP and BNP have been found to be elevated in severe COVID-19 patients—with and without heart failure.
- the serious sick patients have higher proBNP and BNP markers (REFERENCE 3). Therefore, one could surmise that COVID-19 causes an elevated NP.
- the present invention is based on administering, early in the course of the disease, one or more NPs to COVID-19 patients to increase their NP levels, not decrease their NP levels as one could surmise is needed.
- the present invention may administer one or more neprilysin inhibitors (NI) which has been used to treat heart failure.
- NI neprilysin inhibitors
- the Nis are used to block the degradation of NPs, mostly CNP by neprilysin, and thus effectively raise NP levels which could again be counterintuitive to current results.
- NPs used in the present invention have a broad range of beneficial effects that are relevant in each stage of the disease:
- This invention uses combinations of medications, and routes of administration, to increase the benefits of NPs with the following methods:
- a method of treating a corona virus infection in a human comprises administering to the human an effective amount of at least one a natriuretic peptide (NP) and a neprilysin inhibitor (NI).
- NP natriuretic peptide
- NI neprilysin inhibitor
- a method of treating or mitigating symptoms and consequences of a corona virus infection in a human comprises administering to the human a therapeutically effective amount of a pharmaceutical composition; wherein the pharmaceutical composition is at least one of: one of a recombinant B-type natriuretic peptide (rBNP) and a chimeric D natriuretic peptide (CD-NP); recombinant A-type natriuretic peptide (rANP); CD-NP and at least one recombinant natriuretic peptide (rNP), wherein the rNP includes recombinant A-type natriuretic peptide (rANP), recombinant B-type natriuretic peptide (rBNP), and recombinant C-type natriuretic peptide (rCNP); at least one neprilysin inhibitor (NI) inhibitor in the absence of a natriuretic peptide
- a pharmaceutical composition comprises a natriuretic peptide (NP); a neprilysin inhibitor (NI); and a pharmaceutically acceptable carrier.
- NP natriuretic peptide
- NI neprilysin inhibitor
- the inventive treatment/composition can have many benefits in different aspects and stages of the SARS-COV-2/COVID-19 disease.
- cytokine storm In later phases of the disease, it is critical to control the immune response, prevent the cytokine storm, and improve the overall local, systemic, acute, and late immune response. For example, downregulating the ‘cytokine storm’, by directly affecting the immune cells and macrophages to over produce cytokines, prevents autoimmune responses to damaged cells.
- inventive method and composition are in contrast to current approaches, which address a single aspect/stage/organ of the disease.
- FIG. 1 is a depiction of relations between various regulatory systems and disruption of essential pathways and organ systems due to COVID-19.
- FIGS. 2A-2E are a table summarizing COVID-19 systemic manifestations and complication and the NP's effect on each.
- the inventive treatment/composition can use a variety of combinations of medications, doses, routes of administration, and durations of treatment.
- NP Natriuretic Peptides
- NEP neutral endopeptidase
- MME metallo-endopeptidase
- NP Natriuretic Peptides
- Objects of the present invention include:
- NPs and their receptors mediate a diverse array of physiologic effects ranging from the control of blood pressure to regulating the immune and coagulation systems. This broad assortment of responses is achieved from the distinct actions of individual natriuretic peptides interacting with specific guanylyl cyclase receptors.
- A-type Natriuretic Peptide (ANP) A-type Natriuretic Peptide (ANP)
- ANP is degraded from pro ANP, a 28-amino acid peptide.
- ANP has a half-life of approximately 10 minutes in vivo.
- ANP is synthesized as an inactive preprohormone, encoded by the human NPPA gene mostly in the atrial myocytes.
- proANP is released following stimulation of atrial cells, and rapidly converted to the 28-amino-acid ANP on the cell surface by the cardiac transmembrane serine protease Corin also known as ANP-converting enzyme.
- ANPs are secreted from the cardiac atrium as a response to several stimuli.
- Atrial dilatation and stretching of the wall triggering the atrial volume receptors increased sympathetic stimulation of the b receptors, increased sodium concentration, increased Endothelin, which cause vasoconstriction.
- the generic name is CarperitideTM (in Japan) and is AntaridineTM (in USA).
- BNP B-type Natriuretic Peptide
- BNP affects the same receptors as ANP, but with a lower affinity. BNPs have the same physiologic effects as ANPs, but BNPs have a longer half-life of 22 min. BNP is mostly expressed in the ventricles of the heart ventricle and the brain. BNP's cellular mediator is PKG, and it is degraded from pro-BNP, a 32-amino acid peptide also cleaved by Corin or Furin.
- CNP C-type Natriuretic Peptide
- CNPs The main effect of CNPs is to relax the vascular endothelium in response to stimuli such as shear stress (like NO) and certain proinflammatory cytokines.
- CNP is a selective agonist for the B-type natriuretic receptor (NPRB).
- NPRB B-type natriuretic receptor
- the half-life of CNP is about three minutes.
- the precursor pro CNP is cleaved by Furin into CNP.
- DNP D-type Natriuretic Peptide
- DNP resists breakdown by neutral endopeptidase and is 10 times more potent than ANP in stimulating cGMP production in GC-A expressing cells. It exists as ‘DNP-LI’ in human plasma and the atrial myocardium. A 38-amino acid peptide, DNP is also available from the venom of the green mamba snake Dendroaspis augusticeps. Blocking the NPR-C receptor with DNP can replace the action of CNP to promote vasodilation, inhibition of the vascular inflammation, to decrease the thrombotic phenomena, which are serious problems in COVID disease.
- URO Endogenous URO is believed to be produced by the kidney through local synthesis and/or processing of renal or circulating pro-ANP. URO plays a pivotal role in regulation of urinary sodium excretion.
- VNP Ventricular NP
- CD-NP Chimeric natriuretic peptide
- CenderitideTM Chimeric natriuretic peptide
- CD-NP is created by the fusion of the 15 amino acid C-terminus of DNP with the full CNP structure
- This peptide chimera is a dual activator of the natriuretic peptide receptors NPR-A and NPR-B.) (REFERENCE 20).
- AC-NP that combined the 17-amino acid ring of C type natriuretic peptide (CNP) with the 6-amino acid N-terminus and 5-amino acid C-terminus of atrial natriuretic peptide
- VNP VNP (VASONATRIN) which is a chimera of CNP and ANP possessing the 22-amino acid ringed structure of CNP, along with the C-terminus of ANP. (REFERENCE 21).
- NPs act on the following cell surface receptors:
- NPs The binding of NPs to its receptor causes the conversion of GTP to cGMP and raises intracellular cGMP.
- cGMP activates a cGMP-dependent kinase (PKG or cGK) or one or more phosphodiesterase (PDEs), which is the cell mediator for NP.
- PKG or cGK cGMP-dependent kinase
- PDEs phosphodiesterase
- the target receptor such as on the medullary cells of the kidney. It may also directly modulate ion channels.
- the NPR-C lacks guanylyl cyclase activity; instead, receptor activation is coupled to inhibition of Adenyl Cyclase or activation of PLC, phospholipase C; (PLC). Moreover, indirect cGMP signaling downstream from NPR-C occurs through activation of eNOS.
- the NPR-A preferentially binds ANP and BNP
- the NPR-B binds CNP with the highest affinity. All natriuretic peptides bind to the NPR-C, which is the most abundantly expressed throughout the body.
- the broad distribution of the NPRs is indicative of the wide range of biological effects of the natriuretic peptides.
- Cardiac effect inhibit cardiac hypertrophy, and fibrosis, as it inhibits fibroblast proliferation and decreasing inflammation since NPRs are abandoned in cardiac tissue mostly the NRP B.
- NPRs are abandoned in cardiac tissue mostly the NRP B.
- myocardial stretch and insults to the myocardium such as hypoxia there is upregulated expression and release of natriuretic peptides.
- Antifibrotic effects have been demonstrated with in vitro and in vivo administration of CNP and the chimeric analogue CD-NP (created by fusion of CNP and D-type natriuretic peptide).
- Hypertension by suppression of the renin-angiotensin-aldosterone system. Patients with primary hypertension have low level of NPs.
- Atherosclerosis and thickening of the vascular wall have been shown to reduce expression of adhesion molecules such as monocyte chemoattractant protein 1 (also known as C-C motif chemokine 2) and P-selectin both of which are considered pivotal for the activation of endothelial cells and the subsequent infiltration of leucocytes as well as inhibition of intimal thickening resulting from smooth muscle cell migration.
- monocyte chemoattractant protein 1 also known as C-C motif chemokine 2
- P-selectin both of which are considered pivotal for the activation of endothelial cells and the subsequent infiltration of leucocytes as well as inhibition of intimal thickening resulting from smooth muscle cell migration.
- Thrombosis Activated platelets have a role in the atherogenic process by recruiting leucocytes through the formation of platelet-leucocyte aggregates and by secretion of proinflammatory cytokines. In concert with the coagulation and fibrinolytic systems, activated platelets are also involved in thrombosis and in the thromboembolic complications observed in atherosclerosis.
- CNP reduces the expression of platelet P-selectin, reduce platelet-leucocyte interactions, and suppress thrombin-induced platelet aggregation.
- PAI-1 plasminogen activator inhibitor 1
- Adrenal effects reduction of aldosterone and catecholamines from the adrenal gland.
- Vascular smooth muscle relaxation via the cGMP receptors as well as inhibiting the sympathetic system.
- CNS effect All three natriuretic peptides, particularly C-type natriuretic peptide, are produced in the brain. Pressor hormones or amines such as endothelin, vasopressin, and norepinephrine, but not angiotensin II, stimulate the release of atrial natriuretic peptide from hypothalamic neurons which will produce a negative feedback through the pituitary. In the brain stem they act to decrease the sympathetic tone by tonic regulation of cardiovascular baroreceptor signal.
- Pressor hormones or amines such as endothelin, vasopressin, and norepinephrine, but not angiotensin II, stimulate the release of atrial natriuretic peptide from hypothalamic neurons which will produce a negative feedback through the pituitary. In the brain stem they act to decrease the sympathetic tone by tonic regulation of cardiovascular baroreceptor signal.
- GLP-1 glucagon-like peptide 1
- RAAS Renin Angiotensin Aldosterone System
- Natriuretic peptides can help to restore balance in the Renin Angiotensin Aldosterone System (RAAS).
- NPs can help to restore balance in the Renin Angiotensin Aldosterone System (RAAS).
- RAAS Renin Angiotensin Aldosterone System
- NPs block Renin, the enzyme that cleaves Angiotensinogen into Angiotensin I, which reduces the amount of Angiotensin II that can be converted by ACE. This action also reduces the ratio of ACE to ACE2.
- the RAAS interacts with the KKS via ACE, ACE2, and Ang II, which means that an imbalanced RAAS can contribute to an imbalanced KKS. Therefore, the balancing effects of NPs on the RAAS can also help to balance the KKS.
- NPs help to balance the sympathetic system by reducing the levels of aldosterone and catecholamines, and by inhibiting the release of the neurotransmitter norepinephrine by the sympathetic nerve terminals.
- NPs can also balance the RAAS, and reduce levels of Ang II, which influences the sympathetic system and raises blood pressure.
- the coagulation system is responsible for atherosclerosis (depositing plaques of fatty material on the inner walls of arteries) and thrombosis (formation of blood clots).
- NPs help to control to these effects in the following ways:
- ROS Reactive Oxygen Species
- NPs In the beginning of an infection, NPs promote the ROS reaction which is one of the cell's responses to invasion. Later in the process, NPs will counter-regulate the ROS to avoid their overexpression.
- ROS Reactive Oxygen Species
- the NPs also help to regulate the production of the ROS and Nitric Oxide (NO) because excess levels of these compounds are harmful to the body.
- Natriuretic peptides serve as a counter-regulatory system for the renin angiotensin aldosterone system (RAAS).
- RAAS renin angiotensin aldosterone system
- NPs help to control the proliferation of immune cells. NPs are expressed in lymphoid tissues such as thymus, lymph nodes spleen and in macrophages.
- NPs will induce the natural killer cells (NK) to induce the programmed death of host cells (apoptosis) that are infected by the microbes.
- NK natural killer cells
- apoptosis programmed death of host cells
- IFN interferon
- NPs prime the neutrophil immune cells to induce leukotriene B4 and ROS, to upregulate the marker CD11B, and induce the phagocytic activity of the macrophages.
- the NPs closely regulate the production of the ROS and Nitric Oxide (NO) because excess levels of these compounds are harmful to the body.
- the NPs encourage the T cells to mature into CD4+ and CDS+ cells. This counteracts the virus-induced loss of lymphocyte immune cells (lymphopenia) that occurs in COVID-19.
- NPs promote the hormone thymopoietin and T cell maturation by promoting the dendritic cells.
- ANP regulates the balance between Th1-type cytokines and Th2-type cytokines responses.
- NPs may also inhibit TMPRSS2, the serine protease which must be present for the virus to enter the cell.
- TMPRSS2 is highly expressed in cancer disease.
- NPs have a regulatory effect on various types of cancer through its cGMP receptor. (REFERENCE: 8).
- NPs reduce the production of proinflammatory mediators by inhibiting inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2) as well as TNF synthesis.
- iNOS inducible nitric oxide
- COX-2 cyclooxygenase-2
- ANP also affects the action of TNF: it interferes with the inflammatory effects of TNF on the endothelium. The NP counteracts TNF-induced endothelial permeability and adhesion and the attraction of inflammatory cells.
- NPs reduce the production of proinflammatory mediators by inhibiting iNOS.
- NPs regulate the production of inflammatory mediators in macrophages.
- NPs inhibit the lipopolysaccharide (LPS) induced expression of iNOS in macrophages, and significantly reduce the activation of NF-KB as well as the secretion of tumor necrosis factor a (TNFa) in macrophages and blood.
- LPS lipopolysaccharide
- TNFa tumor necrosis factor a
- NPs will attenuate the production of IL1 13, IL1RA, IL6, IL?, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNy, IP10, MCP1, MIP1a, MIP113, PDGFB, TNFa, and VEGFA, as well as proinflammatory cytokines (PIC), including IL2, IL?, IL10, GCSF, IP10, MCP1, MIP1a, and TNFa.
- PIC proinflammatory cytokines
- NPs are Janus Kinase Inhibitors, and downregulate the JAK 1 and JAK 2 protein, which decreases the inflammatory response. (REFERENCE 18).
- NPS may counteract an exacerbated TH1 response as seen in chronic delayed type hypersensitivity reactions which lead to fibrosis and necrosis of the surrounding tissue.
- NPs affect the sympathetic system, which is over expressed in Covid disease, in several ways:
- NPs In the coagulation system, which is closely related with the KKS, NPs have atherosclerotic and thrombotic control in the following ways:
- NPs decrease the expression of tissue factor and plasminogen activator inhibitor 1 from endothelial cells and vascular smooth muscle cells, which are induced by Ang II.
- ROS System reactive Oxygen Species
- NPs In the beginning of the infection, NPs promote the ROS reaction which is one of the cell's responses to invasion. Later in the process, NPs will counter-regulate the ROS to avoid their overexpression.
- NPs will reduce venous pressure which reduces pulmonary capillary wedge pressure, which in turn reduces pulmonary hypertension and improves ARDS and right-side cardiac failure.
- NPs By rebalancing the RAAS in the lungs, NPs will decrease the number of ACE2 receptors in the lungs that are available for infection by the virus. This will reduce the rate and severity of the viral infection of cells in the lungs and reduce the number of new viruses that can infect other cells.
- Improving the immune response to protect against secondary infections may also reduce the hypoxia.
- NPs also help to rebalance the Reactive Oxygen Species (ROS) system, which helps to increase oxygenation and reduce radical products.
- ROS Reactive Oxygen Species
- NPs can help to improve the function of the Central Nervous System and respiratory regulatory centers which may be affected by COVID-19 and contribute to the hypoxia.
- NPs improve the performance of the myocardium in the heart, which experiences a higher ‘workload’ when there is vasoconstriction and hypoxia.
- NPs may be a mechanism for compensating for extreme environments and healing injuries to organs. For example, researchers have observed elevated NPs in healthy people at high altitudes, and in patients with high altitude sickness and sleep apnea. In stress tests researchers have observed elevated levels of B-type NPs (REFERENCE 9, 10).
- NPs mitigate hyper coagulopathy and micro thromboembolism through direct effects on the RAAS and the Coagulation Cascade, as described previously.
- NPs provide the following benefits for cardiac involvement in the disease:
- ANP inhibits the renal sympathetic system that cause vasoconstriction.
- NPs help to control hypertension by balancing the RAAS which reduces Ang II, which in turn reduces vasoconstriction and increases vasodilation.
- the mechanism of systemic vasodilation also involves NP receptor-mediated elevations in vascular smooth muscle.
- NPs dilate veins This increase ‘venous compliance’ which decreases the central venous pressure, which reduces cardiac output by decreasing ventricular preload.
- NPs dilate arteries which decreases systemic vascular resistance and systemic arterial pressure. The mechanism of systemic vasodilation involves NP receptor mediated elevations in vascular smooth muscle.
- NPs induce the following:
- NPs may also have the effect of reducing anxiety.
- Neprilysin catalyzes the degradation of NPs. This action contributes to the short half-lives of NPs (typically 2 to 20 minutes).
- Neprilysin is a cell membrane-bound neutral endopeptidase (NEP), a metallo-endopeptidase (MME) that is expressed throughout the body, including the central nervous system, the kidneys, and vascular system, and the neutrophils, lymphocytes, and lymphoid progenitors in the immune system.
- NEP cell membrane-bound neutral endopeptidase
- MME metallo-endopeptidase
- Neprilysin is a member in metallopeptidases (MME), which include, NEP2, ECE1, ECE2 (endothelin converting enzyme) and phosphate regulated neutral endopeptidase (PHEx).
- Neprilysin has been observed generating and degrading many bioactive peptides in vitro, but the mechanism and the effect of metabolizing those peptides with similar and counteracting activity, is not well understood. Because neprilysin is just one of many peptidases that degrade peptides, the net effect of neprilysin should only be considered in vivo and not in isolation.
- Neprilysin could be used as a biomarker to indicate the effectiveness of the proposed treatment on lymphopenia in COVID and other diseases. Neprilysin also exists in soluble form in the blood and cerebral spinal fluid and so can be used as a biomarker. (REFERENCE 15). Because Neprilysin is abandoned in lymphoid progenitors in the immune system such as early B, pro-B and pre-B, Neprilysin is used as a marker known as the common acute lymphoblastic leukemia antigen (CALLA). Neprilysin/CALLA is highly positive in acute lymphatic leukemia and hematological diseases, and it could be used as a biomarker to indicate the effectiveness of the proposed treatment on lymphopenia in COVID and other diseases.
- CALLA common acute lymphoblastic leukemia antigen
- Neprilysin Inhibitors By blocking the action of Neprilysin, Neprilysin Inhibitors limit the degradation of NPs. This can extend the availability of naturally occurring NPs and enhance their beneficial effects. (REFERENCE 5). Neprilysin Inhibitors also have a negligible inhibitory effect on other metallopeptidase such as NEP2, ECE1, ECE2.
- Neprilysin inhibitors have a variety of other effects that are relevant to the treatment of coronavirus infections, as follows:
- the routes of administration of the treatment will depend on the patient's condition, preferences, and state of health.
- the routes that may be used include the following:
- the treatment can be tailored to reflect the specific symptoms and complications that each patient experiences.
- the particular affinities of the A-type NP may be included or emphasized in the treatment when the following conditions are present:
- the B-type NPs may be included or emphasized in the treatment when there is cardiac failure or involvement of the central nervous system and its essential regulatory centers. (and regulatory systems).
- the C-type NPs may be included or emphasized in the treatment to prevent or mitigate (hypercoagulation and) thromboembolic phenomena.
- the timing of the treatment may also be tailored to reflect the specifics of each patient's condition and situation. For example, if the treatment is intended to be a preventative measure for a patient who was exposed to a known carrier of SARS-COV-2, the recommended treatment would be from 14 to 21 days, or at the incubation period of the virus. For this it may be applicable to use a rectal suppository, to prevent GI shedding and spreading, buccal, or sublingual, nasal spray, inhalation, or to prevent and mitigate the respiratory spreading and the following lung injury and ARDS or as preventing in exposed individual and community.
- IV intrabrachial treatments of 3 to 4 days with high doses may be indicated.
- intrathecal route When there are neurological complications, such as encephalitis and neurological deficits, it may be advisable to use intrathecal route.
- the treatment is administered in the form of recombinant BNP (such as NatrecorTM which is manufactured by Janssen) with an initial IV bolus of 2 mcg/kg, followed by a continuous infusion of flow rate of 0.01 mcg/kg/min for up to 96 hours.
- BNP recombinant BNP
- the dose-limiting side effect of NatrecorTM is severe hypotension. Do not initiate the treatment if systolic blood pressure is less than 110.
- the treatment is administered in the form of ANP human recombinant, such as CarperitideTM (manufactured by Daiichi Sankyo, Japan) in a low dose such as intravenous 0.02 mcg/kg/min for up to 72 hours.
- ANP human recombinant such as CarperitideTM (manufactured by Daiichi Sankyo, Japan) in a low dose such as intravenous 0.02 mcg/kg/min for up to 72 hours.
- the treatment is a combination of recombinant ANP, BNP, and CNP, administered by IV, with the following doses: ANP with a continuous infusion of 0.02 mcg/kg/min; and BNP with a continuous infusion of flow rate of 0.01 mcg/kg/hr; and CNP with a continuous infusion of 0.001 mcg/kg/min.
- the medications are administered for up to 96 hours or until the desired clinical effects are achieved. This may be indicated for heart failure and/or thrombosis or microangiopathy.
- Neprilysin Inhibitor (Sacubitril) and ARB (Valsartan), commercially available as EntrestoTM, Administered Via Tablet
- Another example of the treatment is a combination of sacubitril and valsartan, administered as a tablet twice daily, with increasing doses as tolerated, beginning at 50 mg (24 mg sacubitril/26 mg valsartan) and increasing to 100 mg (49/51 mg) and then to 200 mg (97/103) mg. The treatment is continued until the clinical effects are achieved.
- the treatment is sacubitril administered orally, twice daily, with a dose of 100 mg BID The treatment is continued until the clinical effects are achieved.
- the treatment is a combination of NPs (ANP, BNP, CNP) and sacubitril administered as a continuous infusion in a clinically appropriate dose such as a total of 0.01 mcg/kg/min for the NPs and 100 mg BID for the sacubitril.
- ANP, BNP, Sacubitril Administered Via Intrathecal Injection
- the treatment consists of ANP, BNP, and sacubitril, administered via a single injection into the spinal column (intrathecal).
- the doses are the lowest doses of to avoid neurotoxicity. This may be indicated for involvement of the Central Nervous System.
- Inhalation route might be very important in preventing lung injury and further ARDS; by preventing the endothelial permeability as well as shedding virus infected ace2.
- a soluble ANP CarperitideTM
- Carperitidern 1 cc 0.01 mcg /cc concentration which will make it a concentration of 0.001 mcg/cc in propellant HFA ⁇ 134a (1,1,′1,2 tetrafluoroethane) and ethanol. apply at about 3 times a day.
- This route may prevent and mitigated gastrointestinal symptoms complication and long-time virus spreading.
- the recommended dose of NATRECORTM is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min up to 96 hours. Do not initiate NATRECORTM at a dose that is above the recommended dose.
- the loading dose may not be appropriate for those with low systolic blood pressure (SBP) ⁇ 110 mm Hg or for patient.
- CarperitideTM or A anaritide (AuriculinTM, or human atrial natriuretic peptide, amino acid residues 102 to 126; Scios, Mountain View, Calif.) compares favorably to NesiritideTM in several ways; it has a shorter half-life (2 minutes), does not mandate bolus infusion, and is used mostly as a single.
- a combination of Nesiritidern but half the dose a single administration re a bolus of an IV bolus of 1 mcg/kg (to omit if blood pressure is ⁇ “110) followed by a continuous infusion of 0.005 mcg/kg/min up to 96 hours, and CarperitideTM (manufactured by Daiichi Sankyo, Japan) (Anaritide) in a low dose such as slow rate of Intravenous 0.005-0.01 mcg/kg/min tor up to 72 hours,
- Neprilysin Inhibitor (Sacubitril) and ARB (Valsartan)
- Sacubitril/Valsartan (LCZ696); available as Entresto by Novartis. Sacubitril (24 mg, 49 mg, or 97 mg) and valsartan (26 mg, 51 mg, or 103 mg).
- the valsartan component in this combination has a higher bioavailability as compared to regular valsartan tablets; therefore, valsartan 26 mg, 51 mg, and 103 mg in the brand-name combination are equivalent to valsartan 40 mg, 80 mg, and 160 mg in other formulations, respectively. To be given from the exposure for at least a month.
- NP as described in single NP above such as 3 days of the above one of the NP with the doses and preparation as described for a single dose.
- ANP and BNP will use both ANP and BNP as a combination of NesiritideTM but half the dose a single administration re a bolus of an IV bolus of 1 mcg/kg (to omit if blood pressure is ⁇ 110) followed by a continuous infusion of 0.005 mcg/kg/min up to 96 hours and CarperitideTM (manufactured by Daiichi Sankyo, Japan) (Anaritide) in a low dose such as slow rate of Intravenous 0.005-0.0i mcg/kg/min for up to 72 hours and Sacubitril (24 mg, 49 mg, or 97 mg). It may be useful to start Sacubitril before or together with the NP.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a divisional application of U.S. Ser. No. 17/221,009 filed Apr. 2, 2022, which claims the benefit of and priority to U.S. provisional application No. 63/006,580 filed Apr. 7, 2020 and 63/050,003 filed Jul. 9, 2020, both of which are incorporated herein by reference in their entireties.
- The present invention relates to methods and compositions for the treatment or prevention of SARS-CoV-2 (COVID-19) independent on the mutation, and other corona virus such as but not only, MERS, COV1, and other RNA and DNA viruses.
- Pathophysiology of SARS-COV-2 and Other Corona Virus Infections
- SARS-CoV-2 and other corona viruses are RNA viruses that infect living cells to reproduce. The virus enters the cell, replicates inside the cell, kills the cell, releases and infect other cells, creates a severe immune response cytokine storm, hypercoagulation, hypoxia, organ complications and death.
- Mutations
- RNA viruses have high mutation rates both random and adaptive—up to a million times higher than their hosts - and these high rates are correlated with enhanced virulence and evolvability, ultimately lead to escape from our current therapeutic and prophylactic interventions.
- Cell Entry
- The angiotensin-converting enzyme 2 (ACE2) receptor is present in humans and other species, which may explain the cross-species transmission. The ACE2 receptor is highly expressed in all organs but mostly in the lungs, nasopharynx, liver, pancreas, kidney, cardiovascular system, central nervous systems, and digestive system.
- The outer membrane of the SARS-CoV-2 virus is speckled with spiky proteins, which act as an anchor to the cell's ACE2 receptor. These SARS-CoV entry-activating proteases include cell surface protease transmembrane serine proteases TMPRSS2 and HAT and lysosomal proteases cathepsins and ADAM17. Moreover, its cell entry is preactivated by proprotein convertase Furin, reducing its dependence on target cell proteases for entry.
- Viral Endocytosis
- The critical step in any viral infection involves penetration of the viral particles into the cytosol; to this end, most viruses take advantage of the endocytic membrane trafficking of the host cell.
- Viral Infection Process
- The pattern recognition receptors (PRRs) which are proteins expressed mainly, by cells of the innate immune system, such as dendritic cells, macrophages, monocytes, and neutrophils, are activated, and trigger the secretion of cytokines. Among these,
type 1/111 interferons (IFNs) are considered the most important for antiviral defense, but other cytokines such as proinflammatory tumor necrosis factor alpha (TNF-a), interleukin-1 (IL-1), IL-6 and IL-18 are also released. - However, compared to other RNA virus, SARS-CoV-2 proteins, such as ORF9b, indirectly interact with the interferon pathway IFN-I, dysregulate and makes the virus virulent as it is.
- Downregulating the ACE2 Receptors
- The SARS-COV-2 spike protein binds very efficiently with the ACE2 receptor causing it to become ‘downregulated’ and nonfunctional by cleaving from its ‘transmembrane domain’, ‘shedding’ of the extracellular portion which makes the ACE2 receptor to be ‘nonfunctional’ and unable to perform its normal functions.
- The downregulation of the ACE2 receptors leads to an increase in ACE and Ang II in the RAAS. This is critical because the ACE/Ang II/AT1 R axis plays an important role in promoting inflammation, vasoconstriction, hyper-coagulopathy and tissue damage, which contributes to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) and other organ failure which are the most serious complications of SARS-COV-2 and COVID-19.
- Dysregulating the RAAS System and Other ‘Cross Talk Axes’ (
FIG. 1 ) - The disequilibrium from a healthy state in essential pathways and systems is probably the root cause of many COVID-19 morbidities. The above mechanism is in the root of the broader deranged systems. This includes the dysregulation of the Renin-Angiotensin-Aldosterone System (RAAS) and other axes that interact, and ‘cross talk,’ with the RAAS and each other. These cross-talking axes include the Kinin-Kallikrein System (KKS), the immune system, the sympathetic and parasympathetic systems, the reactive oxygen species (ROS) and the coagulation pathways.
- COVID-19′s dysregulation of the RAAS produces an imbalance between its two axes: the ‘ACE/Angiotensin II/AT1R’ axis and the ‘ACE2/Angiotensin (1-7)/MAS’ axis.
- Dysregulating the Kinin-Kallikrein System
- The Kinin-Kallikrein System (KKS) with its main players, Bradykinin (BK) and kallidin (KO), has an important role in inflammation, pain, blood pressure control, and coagulation. The KKS interacts with the RAAS, and imbalances in one system can affect the other system and lead to serious complications.
- Kallikreins are responsible for regulating blood pressure, activating inflammation and vasodilatation as well as fibrinolysis.
- The RAAS interacts with the KKS by the ACE which is (also known as Kininase II) which deactivates mainly the bradykinin and by ACE2 that decrease the activity of the des-Arg9 bradykinin/BKB1R axis, which results in the release of pro-inflammatory chemokines. (REFERENCE 1).
- Reactive Oxygen Species (ROS)
- Oxidative stress, originally described as an altered balance between the production of free radicals and antioxidant defenses, is an important phenomenon in different physiological and pathological processes. Several enzymes, including xanthine oxidase, cytochrome P450 monooxygenase, the cyclooxygenase pathway of arachidonic acid metabolism, the plasma membrane NADPH oxidases, and in particular the components of the mitochondrial respiratory chain participate in oxidative stress.
- During oxidative stress, several types of ROS can be generated including the superoxide anion (02-), hydroxyl radical (.OH) and hydrogen peroxide (H2O2), which are essential in cell signaling mechanisms.
- Immune Response, Cytokine Storm, and Runaway Inflammation
- The viral infection triggers a first response by the body's Innate Immune system.
- The dysregulation of the interferon IFN-1 plays a major role in the virulence of SARS-COV-2. (REFERENCE 14).
- The infected cells release ‘immune mediators’, cytokines and chemokines, which when in excess, cause severe inflammation. The types of cytokines include Pro-inflammatory Cytokines: the interleukin IL-1 and Tumor Necrosis Factors (TNF);
Type 1 Cytokines such as TNFa and the Interferon IFN-y; and Type2 Cytokines such as: the interleukins IL-4, IL-10, and IL-13, and the Transforming Growth Factor (TGF). - T cells are also heavily involved in the process. However, in COVID-19 the T cell response is seriously affected by an overall reduction of CD4+ and CDS+ T cells, with short- and long-term severe effect.
- Even further, in parallel with the accelerating production of cytokines by the immune cells, the SARS-COV-2 virus is infecting and destroying the T cells and decreasing the CD4+ and CDS+T cells. with lymphopenia eventually reaching ‘lymphocyte exhaustion,’ which increases the risk of serious secondary infections.
- Late Immune Response with Autoimmunity Manifestations
- The link between infections generally and autoimmune responses is not new.
- In COVID-19, disease severity and poor clinical outcomes are closely correlated with intense activation of the Effectors B cell pathway despite tile presence of high titers of anti-SARS-CoV-2 RBD antibodies with serum-neutralizing activity.
- The SARS-COV-2/COVID-19 disease progresses through four clinical phases with:
- Phase 1: Incubation
- The incubation period ranges from 1-21 days on the average. The main access by the virus is through the upper respiratory tract, nasopharynx, and mucosal secretions through the eyes and nose, as well as the gastrointestinal systems through the feces (‘fecal oral’ transmission).
- Phase 2: Early Infection
- This stage begins with the onset of symptoms. which are typically mild and non-specific (i.e., malaise, cough, fever, etc.)
- Phase 3: Pulmonary Involvement
- This stage is characterized by lungs involvement, with viral pneumonia, cough, fever, and possibly hypoxia, in different degrees, from mild to severe.
- Phase 4: Severe (Systemic Hyperinflammation)
- This stage is denoted by systemic organ failure beyond the lungs. Between 20 and 30% of hospitalized COVID-19 patients are admitted to the ICU, and most of them die.
- This phase is signified by extreme elevated cytokines such as, IL-2, IL-6, IL-7, granulocyte-colony stimulating factor (GCSF), macrophage inflammatory protein 1-alpha, TNF alpha, CRP, ferritin, and D-dimer, as well as elevated troponin and Brain Natriuretic Peptide (BNP) with several clinical complications including hypoxia, due to lung inflammation and infection, due to the ACE2 shedding, the overexpressed ACE/Angiotensin II, under expressed ACE2, the viral and secondary infection, as well as decreased shunt due to vasoconstriction. Also, other main organs malfunction which contributes to the hypoxia—the Central Nervous System (CNS) with dysregulation of the respiratory regulatory centers, due to the same driving forces, kidney, and heart failure.
- Coagulation
- One of the most severe complications of COVID-19 is micro-thromboembolism in the brain and other organs, and in small blood vessels throughout the body (‘disseminated intravascular coagulation’ or DIC). This is caused by the dysregulation of the RAAS and imbalances between ACE and ACE2 and their counter-regulating axes, the dysregulated KKS and bradykinin systems, the systemic inflammation, the vasculature inflammation, and constriction.
- Organ Complication Summary
- The deterioration and dysfunction of the essential systems makes organ complications inevitable and may also lead to death. Including lungs, cardiac, kidney, liver, central nervous system, coagulation decompensation with thromboembolic and DIC, immune system decompensation, including CD4+ and CDS+ immune cell deficiency, rhabdomyolysis and myositis, post infection and chronic fatigue syndrome.
- The complications may include also:
-
- Lungs: complications such as ARDS, hypoxia, and post infection fibrosis
- Heart: cardiac decompensation such as myocarditis, pericarditis, arrhythmia, heart attack, and failure
- Kidney failure
- Liver failure
- Gastrointestinal complication such as diarrhea, severe abdominal pain, gastric bleeding ulcers and perforations
- CNS: Increased risk of strokes, hemorrhagic encephalopathy, Acute disseminated encephalomyelitis (AMED), excited delirium Leukoencephalopathy posterior reversible encephalopathy syndrome. Since the cerebellum and the brain stem have ACE2 receptors, many of the control centers for vital body functions, such as heart rate, blood pressure and respiration as well as swallowing, and vasomotor control will be affected.
- Peripheral Nervous System (Anosmia, hypogeusia, Guillain barre polyneuritis, and other peripheral neuropathy
- Myasthenia gravis, (acute and chronic), as a result of antibodies cross-reacting with AchR subunits since the virus has epitopes similar to components of the neuromuscular junction.
- Coagulation decompensation with thromboembolic and DIC
- Rhabdomyolysis and myositis, myopathy, post infection and chronic fatigue syndrome
- Involvement of the Reproductive systems, (REFERENCE 16)
- Involvement of the Endocrine system (adrenal, thyroid, parathyroid and CNS) and Apocrine systems
- Dermatology: The receptor of SARS-CoV-2, ACE2, was found to be expressed on skin, mainly on keratinocyte. As a result, there are skin manifestations, some are severe, such as Erythema, Chilblain-like lesions, Urticaria-like lesions, Vesicular, Livedo/necrosis, Petechiae, Accompanied by pruritus.
- Immune system: Hemophagocytic lymphohistiocytosis (HLH), related to the failure to control the immune response that results in a hyperinflammatory state and consequently to tissue destruction. Immune system decompensation, including CD4+ and CDS+ deficiency Low levels of natural killer cells. anemia and more.
- Many different types of medications have been evaluated as possible treatments for COVID-19, to name few of them: (REFERENCE 22).
-
- Antiviral Drugs such as anti-HIV, (protease inhibitors, like Lopinavir, Ritonavir), anti-Hepatic C (Ribavirin), anti influenza (Umifenovir, EIDD-2801, and Remdesivir)
- Anti-Parasitic and Anti-Bacterial Drugs such as anti-malarial (Hydroxychloroquine, and chloroquine), anti-bacterial (Azithromycin) and anti-parasitic (Ivermectin)
- Anti-Cancer Medications such as Sirolimus plus Dactinomycin
- TMPRSS2 inhibitor such as Camostat mesylate
- Immune-Based Therapy such as COVID-19 Convalescent Plasma or SARS-CoV-2 Immune Globulins
- Immune Modulators such as Fingolimod
- Interleukin-1 Receptor AntagonisVInhibitors such as Anakinra.
- Interleukin-6 inhibitors such as Sarilumab and Tocilizumab
- Interferons-Interferon a, Interferon 13-113
- Janus Kinase Inhibitors such as Baricitinib, Bemcentinib,
- Anti VEGF (Vascular endothelial growth factor), such as Bevacizumab
- Colchicine
- HMG-CoA Reductase Inhibitors (Statins)
- Anticoagulants of all types such as heparin, coumadin, Arixtra, dabigatran, or aspirin
- Recombinant Ace2
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- Corticosteroids
- Vaccines
- Though Vaccines are becoming available it seems that on the new emerging variants they may be less effective.
- Mutationally, this virus is traveling in a direction that could ultimately lead to escape from our current therapeutic and prophylactic interventions.
- Conclusion
- No medication or course of treatment has been shown to have significant clinical benefits for a broad range of patients, especially at earlier stages of the disease and/or to prevent the progression of the disease to the acute stage. Vaccinations are still in early stages, the effect on mutations is still unveiled, and the long-term sequela are not known.
- In addition, no treatment is available to address the involvement of specific organs.
- Clearly, there is need for more effective treatments/compositions for a wider range of patients, complications, and stages of the disease.
- The invention is of novel methods and compositions for treating subjects with SARS-COV-2 infection (COVID-19) and related viral infections, diseases, and conditions.
- As used herein, the terms “SARS-COV-2” and/or “COVID-19” are intended to refer not only to SARS-COV-2 and COVID-19 but also to mutations/variants thereof. Examples of some mutations/variants include: B.1.1.7 (a.k.a. 201/501 Y.V1); 69/70 deletion; P681 H; the South African variant, known as B.1.351 lineage (a.k.a. 20H/501 Y.V2); Manaus variant; the Brazilian variant; P.1 variant; and P.1 lineage.
- To date, treatment methods have primarily focused on single points in the disease process, and they have achieved limited results for narrow groups of patients. In contrast, the invention is based on the insight that COVID-19 is a disease of imbalanced systems and the complications that result from the interaction of these imbalances, and that an effective treatment/composition for this disease must address these imbalances and complications as a system, for all stages of the disease and for a wide range of subjects.
- This invention is based on the insight that SARS-COV-2 infection, COVID-19, and related diseases cause a cascade of critical intertwined systemic pathway imbalances causing serious complications that can seriously impact the patient's health.
- Natriuretic Peptides (NPs) are the foundation of this inventive treatment/composition/drug combinations. NPs are a natural response to injuries and extreme conditions that cause imbalances in critical systems (for example, heart failure and high-altitude sickness, oxidative stress).
- At the time of writing there are 6 known subtypes that share many structural and physiological properties but also differ from one another. A-type NP (ANP), B-type NP (BNP), C-type NP (CNP), D-type NP (DNP), Urodilatin and VNP (ventricular NP).
- The inventive use of NPs for the treatment of SARS-COV-2 infection and other corona virus infections in humans is counterintuitive to current science. NPs (specifically, proBNP and BNP) have been found to be elevated in severe COVID-19 patients—with and without heart failure. Moreover, the serious sick patients have higher proBNP and BNP markers (REFERENCE 3). Therefore, one could surmise that COVID-19 causes an elevated NP.
- However, the present invention is based on administering, early in the course of the disease, one or more NPs to COVID-19 patients to increase their NP levels, not decrease their NP levels as one could surmise is needed. In addition to, or in lieu of, administering NPs, the present invention may administer one or more neprilysin inhibitors (NI) which has been used to treat heart failure. In the present invention, the Nis are used to block the degradation of NPs, mostly CNP by neprilysin, and thus effectively raise NP levels which could again be counterintuitive to current results.
- For patients with COVID-19 and similar diseases, NPs used in the present invention have a broad range of beneficial effects that are relevant in each stage of the disease:
-
- Reducing the rate of the initial viral infection and the extent of the infection in different organs and systems
- Preventing the overactivation of the immune system, AKA cytokine storm
- Rebalancing the regulatory pathways that are dysregulated by the viral infection and the body's immune responses to the infection, such as the RAAS, ROS, coagulation pathway, and sympathetic system.
- Repairing the damage to cells and tissue that result from the infection the inflammation and the runaway immune responses, and the hypoxia.
- This invention uses combinations of medications, and routes of administration, to increase the benefits of NPs with the following methods:
-
- Extending the availability and the effects of the NPs in the body by limiting the natural processes that degrade NPs, for example using Neprilysin Inhibitors to block the degradation of NPs by neprilysin.
- Increasing the concentration, availability, and effects, of NPs in the body by introducing additional NPs into the body including but limited to specific, homologous recombinant ANP, BNP, CNP, and chimeric DNP.
- Complementing and enhancing the effects of the NPs with other compounds that contribute to rebalancing the overall homeostasis, such as but not only the other neprilysin inhibitor benefit, for example increasing oxytocin and glucagon which are anti-inflammatory.
- In one aspect of the present invention, a method of treating a corona virus infection in a human comprises administering to the human an effective amount of at least one a natriuretic peptide (NP) and a neprilysin inhibitor (NI).
- In another aspect of the present invention, a method of treating or mitigating symptoms and consequences of a corona virus infection in a human comprises administering to the human a therapeutically effective amount of a pharmaceutical composition; wherein the pharmaceutical composition is at least one of: one of a recombinant B-type natriuretic peptide (rBNP) and a chimeric D natriuretic peptide (CD-NP); recombinant A-type natriuretic peptide (rANP); CD-NP and at least one recombinant natriuretic peptide (rNP), wherein the rNP includes recombinant A-type natriuretic peptide (rANP), recombinant B-type natriuretic peptide (rBNP), and recombinant C-type natriuretic peptide (rCNP); at least one neprilysin inhibitor (NI) inhibitor in the absence of a natriuretic peptide NP; at least one each of an rNP, CD-NP, and NI; and one of multiple rNPs and multiple CD-NPs, with at least one NI, wherein the rNPs only include rANP and rBNP.
- In a further aspect of the present invention, a pharmaceutical composition comprises a natriuretic peptide (NP); a neprilysin inhibitor (NI); and a pharmaceutically acceptable carrier.
- Summary of the Clinical Effects of the Inventive Treatment/Composition
- The inventive treatment/composition can have many benefits in different aspects and stages of the SARS-COV-2/COVID-19 disease.
- In the initial viral infection phase, it is crucial to decrease the amount of ACE2 available to virus, block the collaborator protein TMPRSS2, improve the innate immune system response, prevent a state of lymphopenia and CD4+ and/or CDS+ deficiency, as well as interfere with the virus' effect on the initial expression of Interferon I.
- In later phases of the disease, it is critical to control the immune response, prevent the cytokine storm, and improve the overall local, systemic, acute, and late immune response. For example, downregulating the ‘cytokine storm’, by directly affecting the immune cells and macrophages to over produce cytokines, prevents autoimmune responses to damaged cells.
- This can be achieved by the wide range of fundamental effects on the regulatory systems, RAAS, decreasing the ACE/ACE2 ratio, decreasing angiotensin II/angiotensin 1-7 ratio, balancing the KKS, the ROS, and NO production as well as the coagulation and sympathetic systems.
- The inventive method and composition are in contrast to current approaches, which address a single aspect/stage/organ of the disease.
-
FIG. 1 is a depiction of relations between various regulatory systems and disruption of essential pathways and organ systems due to COVID-19. -
FIGS. 2A-2E are a table summarizing COVID-19 systemic manifestations and complication and the NP's effect on each. - The disclosure and its various embodiments can now be better understood by turning to the following detailed description of the preferred embodiments which are presented as illustrated examples of the embodiments defined in the claims. It is expressly understood that the embodiments as defined by the claims may be broader than the illustrated embodiments described below.
- The following detailed description is of the best currently contemplated modes of carrying out the invention. The description is not to be taken in a limiting sense but is made merely for the purpose of illustrating the general principles of the invention, since the scope of the invention is best defined by the appended claims.
- Various inventive features are described below that can each be used independently of one another or in combination with other features. However, any single inventive feature may not address any of the problems discussed above or may only address one of the problems discussed above. Further, one or more of the problems discussed above may not be fully addressed by any of the features described below.
- The inventive treatment/composition can use a variety of combinations of medications, doses, routes of administration, and durations of treatment.
- The Natriuretic Peptides (NP), whose clinical and physiological effects are a foundation of the inventive treatment/composition, and other medications that may protect the NPs and enhance the effect of endogenous, and exogenous NPs, such as inhibitors of neutral endopeptidase, (NEP), also known as metallo-endopeptidase (MME), in specific, neprilysin inhibitors, decrease the break down and complement their actions and clinical effects by other effects aside from preventing the breakdown.
- Introduction
- Natriuretic Peptides (NP) are a family of genetically distinct peptides with similar structure/function that share common membrane receptors. NPs are expressed in nearly all organs in the body. 6 types of NPs are currently known: A-type, B-type, C-type, D-type Urodilatin and, VNP (ventricular NP). Each type of NP is associated with different organs, receptors, and affinities to the receptors.
- Clinical evidence of NP general benefits and effects:
-
- The natriuretic peptides have been implicated in the protection against atherosclerosis, thrombosis, and myocardial ischemia.
- Identification of natriuretic peptide receptors in a broad range of tissues, including the pancreas, liver, and adipose tissues, implies biological effects beyond pressure-volume homeostasis.
- In population-based studies, low circulating concentrations of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are associated with obesity and metabolic dysfunction.
- Genetically determined increased concentrations of ANP and BNP are associated with reduced blood pressure and reduced risk of hypertension in animal models and in the general population.
- Dysregulation or low levels of the natriuretic peptides contribute to metabolic dysfunction and could lead to cardiovascular complications, such as atherosclerosis, thrombosis, hypertension, and myocardial ischemia, and other metabolic conditions as obesity, hypercholesteremia, glucose intolerance,
type 2 diabetes mellitus. - Elevated levels of NPs are observed when there are injuries to vital organs. For example, BNP is a reliable marker for damage to the heart, such as in heart failure, atrial fibrillation.
- ANP is increased in ARDS, Car Pulmonale and Pulmonary hypertension.
- NP's are increased in high altitude sickness, sleep apnea and extreme exercise. (REFERENCE 9).
- NPs are elevated in COVID-19 Acute Respiratory Distress Syndrome, without heart involvement, (REFERENCE 3), perhaps as a compensating process for respiratory difficulty.
- Objects of the present invention include:
-
- NPs are quickly degraded by other compounds in the body: the half-life of an A-type NP is several minutes, while of B-type NP is 20 minutes. An important aspect of this inventive treatment/composition is to increase the availability of NPs in the body, by first protecting the naturally occurring NPs from degradation, and by introducing additional NPs into the body, as well as maintain their bio effectiveness and functionality.
- Yet more, it may have a synergistic effect with other medications, such as ARB, soluble ACE2, or Guanyl cyclase stimulator (Vergudo) and others.
- NPs and their receptors mediate a diverse array of physiologic effects ranging from the control of blood pressure to regulating the immune and coagulation systems. This broad assortment of responses is achieved from the distinct actions of individual natriuretic peptides interacting with specific guanylyl cyclase receptors.
- A-type Natriuretic Peptide (ANP)
- ANP is degraded from pro ANP, a 28-amino acid peptide. ANP has a half-life of approximately 10 minutes in vivo.
- ANP is synthesized as an inactive preprohormone, encoded by the human NPPA gene mostly in the atrial myocytes. proANP is released following stimulation of atrial cells, and rapidly converted to the 28-amino-acid ANP on the cell surface by the cardiac transmembrane serine protease Corin also known as ANP-converting enzyme. ANPs are secreted from the cardiac atrium as a response to several stimuli.
- Atrial dilatation and stretching of the wall triggering the atrial volume receptors, increased sympathetic stimulation of the b receptors, increased sodium concentration, increased Endothelin, which cause vasoconstriction.
- The generic name is Carperitide™ (in Japan) and is Antaridine™ (in USA).
- B-type Natriuretic Peptide (BNP)
- BNP affects the same receptors as ANP, but with a lower affinity. BNPs have the same physiologic effects as ANPs, but BNPs have a longer half-life of 22 min. BNP is mostly expressed in the ventricles of the heart ventricle and the brain. BNP's cellular mediator is PKG, and it is degraded from pro-BNP, a 32-amino acid peptide also cleaved by Corin or Furin.
- The generic name is Nesiritide™
- C-type Natriuretic Peptide (CNP)
- The main effect of CNPs is to relax the vascular endothelium in response to stimuli such as shear stress (like NO) and certain proinflammatory cytokines. CNP is a selective agonist for the B-type natriuretic receptor (NPRB). The half-life of CNP is about three minutes. The precursor pro CNP is cleaved by Furin into CNP.
- D-type Natriuretic Peptide (DNP)
- DNP resists breakdown by neutral endopeptidase and is 10 times more potent than ANP in stimulating cGMP production in GC-A expressing cells. It exists as ‘DNP-LI’ in human plasma and the atrial myocardium. A 38-amino acid peptide, DNP is also available from the venom of the green mamba snake Dendroaspis augusticeps. Blocking the NPR-C receptor with DNP can replace the action of CNP to promote vasodilation, inhibition of the vascular inflammation, to decrease the thrombotic phenomena, which are serious problems in COVID disease.
- Urodilatin (URO)
- Endogenous URO is believed to be produced by the kidney through local synthesis and/or processing of renal or circulating pro-ANP. URO plays a pivotal role in regulation of urinary sodium excretion.
- The generic version is ULARITIDE™.
- Ventricular NP (VNP)
- Expression has only been confirmed in the hearts of primitive ray-finned bony fish, in which it is responsible for the maintenance of fluid and salt homeostasis.
- Other Chimeric Variations
- Chimeric natriuretic peptide (CD-NP) is also known as Cenderitide™. CD-NP is created by the fusion of the 15 amino acid C-terminus of DNP with the full CNP structure This peptide chimera is a dual activator of the natriuretic peptide receptors NPR-A and NPR-B.) (REFERENCE 20).
- AC-NP that combined the 17-amino acid ring of C type natriuretic peptide (CNP) with the 6-amino acid N-terminus and 5-amino acid C-terminus of atrial natriuretic peptide
- VNP (VASONATRIN) which is a chimera of CNP and ANP possessing the 22-amino acid ringed structure of CNP, along with the C-terminus of ANP. (REFERENCE 21).
- ANX042 Generic name: ASBNP™
- ZD100 Generic name: MANP™ (REFERENCE 17)
- NPs act on the following cell surface receptors:
-
- Guanylyl cyclase-A (GC-A) which is also known as natriuretic peptide receptor-A (NPRA/ANPA) or NPR1
- Guanylyl cyclase-B (GC-B) which is also known as natriuretic peptide receptor-B (NPRB/ANPB) or NPR2
- Natriuretic peptide clearance receptor (NPRC/ANPC) or NPR3 (clearance), which serves both as clearance and as inhibitory G protein.
- The binding of NPs to its receptor causes the conversion of GTP to cGMP and raises intracellular cGMP. As a consequence, cGMP activates a cGMP-dependent kinase (PKG or cGK) or one or more phosphodiesterase (PDEs), which is the cell mediator for NP.
- Those are important regulators of intracellular Ca2+ concentrations by mediating Ca2+ sequestration in the endoplasmic or sarcoplasmic reticulum and downregulation of the L-type Ca2+ channels located in the cell membrane.
- However, it may also work directly on the target receptor such as on the medullary cells of the kidney. It may also directly modulate ion channels.
- The NPR-C lacks guanylyl cyclase activity; instead, receptor activation is coupled to inhibition of Adenyl Cyclase or activation of PLC, phospholipase C; (PLC). Moreover, indirect cGMP signaling downstream from NPR-C occurs through activation of eNOS.
- Whereas the NPR-A preferentially binds ANP and BNP, the NPR-B binds CNP with the highest affinity. All natriuretic peptides bind to the NPR-C, which is the most abundantly expressed throughout the body.
- The broad distribution of the NPRs is indicative of the wide range of biological effects of the natriuretic peptides.
-
TABLE Biological effects of the natriuretic peptides EFFECT PEPTIDE Lipolysis ANP, BNP, CNP Increased mitochondrial respiration and fat oxidation in ANP, BNP skeletal muscle Lowering of blood glucose and insulin levels BNP Decreased gastric emptying and absorption BNP EFFECT PEPTIDE Inhibition of ghrelin (also known as appetite-regulating BNP hormone) and depression of hunger feeling Increase of capacity of thermogenic energy expenditure ANP, BNP in adipocytes Inhibition of leucocyte recruitment and platelet- CNP leucocyte aggregates Inhibition of platelet aggregation CNP Inhibition of expression of adhesion molecules on ANP, CNP endothelial cells Inhibition of smooth vascular cell proliferation and ANP, BNP, CNP migration Decreased expression of tissue factor and plasminogen ANP, BNP, CNP activator inhibitor 1 from endothelial cells and vascular smooth muscle cells Suppression of infarct size resulting from ischemia and ANP, BNP, CNP reperfusion Relaxation of coronary arteries CNP Inhibition of cardiac fibroblast proliferation ANP, BNP, CNP Inhibition of hypertrophy in cardiomyocytes ANP, CNP Inhibition of macrophage infiltration, collagen ANP synthesis, and expression of proinflammatory chemotactic factors in angiotensin II-induced myocardial remodeling Stimulation of chondrocyte proliferation, hypertrophy, CNP and cartilage matrix production Loss-of-function mutations in the genes encoding CNP CNP or NPR-B causes dwarfism Regulation of fetal bone growth CNP Modulation of spermatozoa motility, testicular germ CNP cell development, and testosterone synthesis Relaxation of smooth muscle cells in the myometrium CNP Decrease occular pressure ANP - Cardiac effect: inhibit cardiac hypertrophy, and fibrosis, as it inhibits fibroblast proliferation and decreasing inflammation since NPRs are abandoned in cardiac tissue mostly the NRP B. In response to myocardial stretch and insults to the myocardium, such as hypoxia there is upregulated expression and release of natriuretic peptides. Antifibrotic effects have been demonstrated with in vitro and in vivo administration of CNP and the chimeric analogue CD-NP (created by fusion of CNP and D-type natriuretic peptide).
- Hypoxia: damage prevention in the myocardium for example with acute myocardial infarction. A decrease of nearly 15% in infarct size was reported in patients treated with Carperitide for 3 days compared to placebo. Those cardioprotective effects are because of cGMP and subsequent cGMP-PKG signaling which balance the cellular apoptosis and cells survival through the NPR A and B, but also indirectly through NO generation through the NPR C.
- Hypertension: by suppression of the renin-angiotensin-aldosterone system. Patients with primary hypertension have low level of NPs.
- Atherosclerosis and thickening of the vascular wall; ANP and CNP have been shown to reduce expression of adhesion molecules such as monocyte chemoattractant protein 1 (also known as C-C motif chemokine 2) and P-selectin both of which are considered pivotal for the activation of endothelial cells and the subsequent infiltration of leucocytes as well as inhibition of intimal thickening resulting from smooth muscle cell migration.
- Thrombosis: Activated platelets have a role in the atherogenic process by recruiting leucocytes through the formation of platelet-leucocyte aggregates and by secretion of proinflammatory cytokines. In concert with the coagulation and fibrinolytic systems, activated platelets are also involved in thrombosis and in the thromboembolic complications observed in atherosclerosis.
- CNP reduces the expression of platelet P-selectin, reduce platelet-leucocyte interactions, and suppress thrombin-induced platelet aggregation.
- CNP reduced expression of plasminogen activator inhibitor 1 (PAI-1), which is the major physiological inhibitor of fibrinolysis.
- Adrenal effects: reduction of aldosterone and catecholamines from the adrenal gland.
- Vascular smooth muscle: relaxation via the cGMP receptors as well as inhibiting the sympathetic system.
- CNS effect: All three natriuretic peptides, particularly C-type natriuretic peptide, are produced in the brain. Pressor hormones or amines such as endothelin, vasopressin, and norepinephrine, but not angiotensin II, stimulate the release of atrial natriuretic peptide from hypothalamic neurons which will produce a negative feedback through the pituitary. In the brain stem they act to decrease the sympathetic tone by tonic regulation of cardiovascular baroreceptor signal.
- Dermatological effects: The receptor of SARS-CoV-2, ACE2, was found to be expressed on skin, mainly on keratinocyte. As a result, there are skin manifestations, some are severe, such as Erythema, Chilblain-like lesions, Urticaria-like lesions, Vesicular, Livedo/necrosis, Petechiae, accompanied by pruritus. However, it was proven that ATII has a role in skin healing (REFERENCE 2) since BNP is present in injured skin, suggesting that BNP may play a role in cutaneous wound healing
- Metabolic Effects: (REFERENCE 6).
- Adipose tissue-increase FFA release by inducing lipolysis in a cGMP-dependent in adipocytes.
- Lack of NP's contributes to development of obesity and insulin resistance diabetes.
- Reduction of gastric emptying, suppression of food intake and sensation of hunger, as well as induction of adiponectin expression in adipocytes.
- Treatment of human white adipocytes both with ANP and BNP, independently, has been shown to lead to the induction of functional phenotype characteristics of brown adipocytes, a so-called browning of fat, which increases the capacity for thermogenic energy expenditure.
- Have the effect of glucagon-like peptide 1 (GLP-1) analogues used in the treatment of
type 2 diabetes and obesity. - It has also a cytoprotective effects in the myocardial, vascular smooth, endothelial, and hepatocytes through its control of the oxidative stress.
- NPs are known to have a wide range of effects on the regulatory pathways in the body:
- Renin Angiotensin Aldosterone System (RAAS)
- Natriuretic peptides (NPs) can help to restore balance in the Renin Angiotensin Aldosterone System (RAAS). NPs block Renin, the enzyme that cleaves Angiotensinogen into Angiotensin I, which reduces the amount of Angiotensin II that can be converted by ACE. This action also reduces the ratio of ACE to ACE2.
- Kinin Kallikrein System (KKS)
- The RAAS interacts with the KKS via ACE, ACE2, and Ang II, which means that an imbalanced RAAS can contribute to an imbalanced KKS. Therefore, the balancing effects of NPs on the RAAS can also help to balance the KKS.
- Sympathetic System
- NPs help to balance the sympathetic system by reducing the levels of aldosterone and catecholamines, and by inhibiting the release of the neurotransmitter norepinephrine by the sympathetic nerve terminals. NPs can also balance the RAAS, and reduce levels of Ang II, which influences the sympathetic system and raises blood pressure.
- Coagulation System
- The coagulation system is responsible for atherosclerosis (depositing plaques of fatty material on the inner walls of arteries) and thrombosis (formation of blood clots). NPs help to control to these effects in the following ways:
-
- Inhibiting leucocyte recruitment and platelet-leucocyte aggregates help to avoid the initial formation of the clot.
- Inhibiting platelet aggregation withholds a major component of the blood clot.
- Inhibiting the expression of adhesion molecules on endothelial cells helps to limit inflammation by reduce the permeability of the blood vessel.
- Inhibiting the proliferation and migration of smooth vascular cells helps to control the progression of atherosclerosis in hypertension-induced vascular remodeling.
- NPs also decrease the expression of tissue factor and
plasminogen activator inhibitor 1 from endothelial cells and vascular smooth muscle cells by reducing levels of Ang II. This helps to block the procoagulant effects of these compounds. - Because the Coagulation System and the KKS are closely related, the regulatory effects of NPs on the KKS can indirectly help to balance the Coagulation System.
- Reactive Oxygen Species (ROS)
- In the beginning of an infection, NPs promote the ROS reaction which is one of the cell's responses to invasion. Later in the process, NPs will counter-regulate the ROS to avoid their overexpression.
- Prime the neutrophil immune cells to release Reactive Oxygen Species (ROS), which aids in clearance of the invading microbes. The NPs also help to regulate the production of the ROS and Nitric Oxide (NO) because excess levels of these compounds are harmful to the body.
- As an observation, in severe COVID 19 disease the fatal patients started with very low levels of the proBNP, which accelerated as they approach death (REFERENCE 19).
- Conversely, the patients who made it through recovery started with much higher levels of proBNP, which only increased slightly during hospitalization, and then fell off as they recovered REFERENCE 19).
- Though the following describes possible mechanism(s) of how the present invention occurs, the following are not intended to limit the scope of the present invention.
- Viral Infection, Incubation, Replication
- Natriuretic peptides (NPs) serve as a counter-regulatory system for the renin angiotensin aldosterone system (RAAS). By blocking renin, the enzyme that cleaves Angiotensinogen into Angiotensin I, NPs influence the level of Angiotensin II (Ang II) which increase the levels of ACE and ACE2. This helps to restore equilibrium between the ACE/Ang II/AT1 R axis and ACE2/Ang 1-7/MAS axis.
- Due to the counter-regulatory action described above, the availability of ACE2 receptors for infection by SAR-COV-2 is decreased and aborted. This occurs because the feedback cycle of ACE2 cannot be sustained, and the virulence of the virus is mitigated.
- Improved immune response to pathogens such as viruses and bacteria. NPs help to control the proliferation of immune cells. NPs are expressed in lymphoid tissues such as thymus, lymph nodes spleen and in macrophages.
- In the innate immune response to intracellular microbes such as viruses, NPs will induce the natural killer cells (NK) to induce the programmed death of host cells (apoptosis) that are infected by the microbes. At the beginning of this process, the stimulated NK cells will also secrete interferon (INF) which then activates the macrophages to kill the microbes that have been engulfed by the macrophages (‘phagocytosed’).
- NPs prime the neutrophil immune cells to induce leukotriene B4 and ROS, to upregulate the marker CD11B, and induce the phagocytic activity of the macrophages. The NPs closely regulate the production of the ROS and Nitric Oxide (NO) because excess levels of these compounds are harmful to the body.
- In the ‘delayed’ immune response, the NPs encourage the T cells to mature into CD4+ and CDS+ cells. This counteracts the virus-induced loss of lymphocyte immune cells (lymphopenia) that occurs in COVID-19.
- NPs promote the hormone thymopoietin and T cell maturation by promoting the dendritic cells.
- ANP regulates the balance between Th1-type cytokines and Th2-type cytokines responses.
- NPs may also inhibit TMPRSS2, the serine protease which must be present for the virus to enter the cell. TMPRSS2 is highly expressed in cancer disease. NPs have a regulatory effect on various types of cancer through its cGMP receptor. (REFERENCE: 8).
- NPs reduce the production of proinflammatory mediators by inhibiting inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2) as well as TNF synthesis. (ANP also affects the action of TNF: it interferes with the inflammatory effects of TNF on the endothelium. The NP counteracts TNF-induced endothelial permeability and adhesion and the attraction of inflammatory cells.)
- NPs reduce the production of proinflammatory mediators by inhibiting iNOS.
- NPs regulate the production of inflammatory mediators in macrophages.
- NPs inhibit the lipopolysaccharide (LPS) induced expression of iNOS in macrophages, and significantly reduce the activation of NF-KB as well as the secretion of tumor necrosis factor a (TNFa) in macrophages and blood.
- NPs will attenuate the production of IL1 13, IL1RA, IL6, IL?, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNy, IP10, MCP1, MIP1a, MIP113, PDGFB, TNFa, and VEGFA, as well as proinflammatory cytokines (PIC), including IL2, IL?, IL10, GCSF, IP10, MCP1, MIP1a, and TNFa.
- NPs are Janus Kinase Inhibitors, and downregulate the
JAK 1 andJAK 2 protein, which decreases the inflammatory response. (REFERENCE 18). - NPS may counteract an exacerbated TH1 response as seen in chronic delayed type hypersensitivity reactions which lead to fibrosis and necrosis of the surrounding tissue.
- Because they counter-regulate the RAAS, the other cross talk axes (KKS, immune, sympathetic) can be affected indirectly through the RAAS, as well as through direct actions.
- ACE, ACE2, and Ang II, regulate the KKS. Therefore, the effects of NPs on these proteins will also affect the KKS.
- NPs affect the sympathetic system, which is over expressed in Covid disease, in several ways:
-
- By affecting the adrenal gland or the CNS and inhibiting the release of norepinephrine by the sympathetic nerve terminals.
- Indirectly, by counter regulating the RAAS system, which is also negative controlled by the sympathetic system.
- In the coagulation system, which is closely related with the KKS, NPs have atherosclerotic and thrombotic control in the following ways:
-
- By inhibiting leucocyte recruitment and platelet-leucocyte aggregates
- By inhibiting platelet aggregation
- By inhibiting the expression of adhesion molecules on endothelial cells
- By inhibiting the proliferation and migration of smooth vascular cells
- NPs decrease the expression of tissue factor and
plasminogen activator inhibitor 1 from endothelial cells and vascular smooth muscle cells, which are induced by Ang II. - ROS System (Reactive Oxygen Species)
- In the beginning of the infection, NPs promote the ROS reaction which is one of the cell's responses to invasion. Later in the process, NPs will counter-regulate the ROS to avoid their overexpression.
- Pulmonary Involvement by Several Mechanisms
- NPs will reduce venous pressure which reduces pulmonary capillary wedge pressure, which in turn reduces pulmonary hypertension and improves ARDS and right-side cardiac failure.
- Controlling the Viral Infection in the Lungs
- By rebalancing the RAAS in the lungs, NPs will decrease the number of ACE2 receptors in the lungs that are available for infection by the virus. This will reduce the rate and severity of the viral infection of cells in the lungs and reduce the number of new viruses that can infect other cells.
- Limiting the Runaway Immune Response and the Cytokine Storm
- Lowering the rate of the viral infection will also decrease the shedding of ACE2 receptors from infected cells that contributes to the runaway immune response and damage to lung tissue.
- Improving the immune response to protect against secondary infections may also reduce the hypoxia.
- Improving the Inefficient Respiratory Shunt
- Improving the ARDS and the Inefficient Shunt that is created by severe vasoconstriction in the leftover aerated lungs. The NP will induce vasodilatation and so improve the shunt.
- Controlling Hypercoagulation & Pulmonary Emboli
- By Controlling Hypercoagulation & Emboli they will prevent the Pulmonary emboli, commonly seen in Covid patients.
- Rebalancing the Reactive Oxygen Species
- NPs also help to rebalance the Reactive Oxygen Species (ROS) system, which helps to increase oxygenation and reduce radical products. By reducing oxidative stress, NPs help to improve the toxic condition on the alveoli in the lungs, which can also contribute to the hypoxia.
- Improving the Function of the Central Nervous System
- NPs can help to improve the function of the Central Nervous System and respiratory regulatory centers which may be affected by COVID-19 and contribute to the hypoxia.
- Improving the Performance of the Heart
- NPs improve the performance of the myocardium in the heart, which experiences a higher ‘workload’ when there is vasoconstriction and hypoxia.
- Compensating Mechanism for Injuries and Extreme Conditions
- NPs may be a mechanism for compensating for extreme environments and healing injuries to organs. For example, researchers have observed elevated NPs in healthy people at high altitudes, and in patients with high altitude sickness and sleep apnea. In stress tests researchers have observed elevated levels of B-type NPs (REFERENCE 9, 10).
- Coagulation
- NPs mitigate hyper coagulopathy and micro thromboembolism through direct effects on the RAAS and the Coagulation Cascade, as described previously.
- Cardiac Involvement
- NPs provide the following benefits for cardiac involvement in the disease:
-
- Suppress the infarct size that results from ischemia and reperfusion
- Relax the coronary arteries
- Inhibit proliferation of cardiac fibroblasts
- Inhibit hypertrophy in cardiomyocytes
- Inhibit infiltration of macrophages
- Promote the synthesis of collagen and expression of proinflammatory chemotactic factors in Ang II-induced myocardial remodeling
- Kidney Involvement
- Controlling Natriuresis
-
- Inducing the cGMP receptor mainly affects the medullary collecting duct of the kidney on the Natrium potassium Atpase pump to increase natriuresis.
- Increasing the glomerular filtration rate (GFR) and filtration fraction, which produces natriuresis (increased sodium excretion) and diuresis (increased fluid excretion).
- Unlike most diuretic drugs, the renal effects of NPs are potassium sparing.
- ANP will also increase the filtration rate by direct effect to dilate the afferent arteriole.
- Decreasing circulating levels of Renin, Ang II, and aldosterone, which relaxes the mesangial cells which results in further natriuresis and diuresis.
- Vasoconstriction
-
- Counteracting the vasoconstriction that is induced by Norepinephrine
- Counteracting vasoconstriction by balancing the RAAS and reducing levels of Ang II
- Decreased angiotensin II contributes to systemic vasodilation and decreased systemic vascular resistance
- ANP inhibits the renal sympathetic system that cause vasoconstriction.
- Hypertension
- NPs help to control hypertension by balancing the RAAS which reduces Ang II, which in turn reduces vasoconstriction and increases vasodilation. The mechanism of systemic vasodilation also involves NP receptor-mediated elevations in vascular smooth muscle.
- General Vasoconstriction (Due to Imbalance of the RAAS)
- NPs dilate veins. This increase ‘venous compliance’ which decreases the central venous pressure, which reduces cardiac output by decreasing ventricular preload. NPs dilate arteries, which decreases systemic vascular resistance and systemic arterial pressure. The mechanism of systemic vasodilation involves NP receptor mediated elevations in vascular smooth muscle.
- Hyperglycemia and Metabolic Complications
- NPs induce the following:
-
- Lipolysis increased mitochondrial respiration and fat oxidation in skeletal muscle,
- Lower blood glucose and insulin levels,
- Decreased gastric emptying and absorption,
- Inhibition of ghrelin (also known as appetite regulating hormone)
- Depression of feelings of hunger,
- Increase of capacity of thermogenic energy expenditure in adipocytes.
- Improving the involvement of the gastrointestinal system, leading to decreased fecal virus load. (REFERENCE12)
- Improving the involvement of the endocrine system.
- Improving the involvement of reproductive systems.
- Testicular Complications and Other Reproductive Systems
- NPs have the following effects:
-
- Modulation of spermatozoa motility, testicular germ cell development, and testosterone synthesis,
- Relaxation of smooth muscle cells in the myometrium
- Psychiatric Effects
- As a result of their impact on the brain and regulatory effect on the hippocampus and hypothalamus, NPs may also have the effect of reducing anxiety. (REFERENCE 11)
- Though the following describes possible mechanism(s) of how the present invention occurs, the following are not intended to limit the scope of the present invention
- Neprilysin catalyzes the degradation of NPs. This action contributes to the short half-lives of NPs (typically 2 to 20 minutes).
- Neprilysin
- Neprilysin is a cell membrane-bound neutral endopeptidase (NEP), a metallo-endopeptidase (MME) that is expressed throughout the body, including the central nervous system, the kidneys, and vascular system, and the neutrophils, lymphocytes, and lymphoid progenitors in the immune system. Neprilysin is a member in metallopeptidases (MME), which include, NEP2, ECE1, ECE2 (endothelin converting enzyme) and phosphate regulated neutral endopeptidase (PHEx).
- Neprilysin has been observed generating and degrading many bioactive peptides in vitro, but the mechanism and the effect of metabolizing those peptides with similar and counteracting activity, is not well understood. Because neprilysin is just one of many peptidases that degrade peptides, the net effect of neprilysin should only be considered in vivo and not in isolation.
- Neprilysin degrades many peptides including the following:
-
- Ang I, Ang II, and Ang 1-7 (the most important of the three)
- Bradykinin and kallidin (causing vasodilatation, vascular permeability, pain, inflammation), Note: This effect only occurs with artificially-high doses and combined with Angiotensin-Converting Enzyme Inhibitors (ACEI). (REFERENCE 13).
- Glucagon (anti-inflammatory, lungs protector, stimulate hepatic glucose and ketone production)
- Oxytocin (protective effect in Acute Lung Injury)
- Enkephalins L, M enkephalins (anti-inflammatory and analgesia), oxytocin), glucagon, enkephalins, substance P, neurotensin,
- Adrenomedullin (causing vasodilatation)
- Dynorphin (causing analgesia)
- B endorphin (causing analgesia)
- ACTH (stimulate adrenal corticosteroids secretion)
- CGRP (causing vasodilatation pain inflammation, migraine)
- Bombesin like peptide (a mitogen as well as stimulate gastrin and Cholecystokinin),
- Chemotactic peptide formyl Met-Leu Phe (causing inflammation),
- Cholecystokinin cck8 (stimulates gall bladder, pancreas, and intestinal motility, create sense of satiety)
-
Endothelin 1 and 2 (causing vasoconstriction, mitogenesis, vascular hypertrophy) -
FGF 2,fibroblast growth factor 2, (causing angiogenesis) - Galanin (inhibits neurotransmitter release)
- Bastrin releasing peptide (a mitogen, stimulation of gastrin, somatostatin and CCK and gastric acid)
- Another important aspect of this invention is that Neprilysin could be used as a biomarker to indicate the effectiveness of the proposed treatment on lymphopenia in COVID and other diseases. Neprilysin also exists in soluble form in the blood and cerebral spinal fluid and so can be used as a biomarker. (REFERENCE 15). Because Neprilysin is abandoned in lymphoid progenitors in the immune system such as early B, pro-B and pre-B, Neprilysin is used as a marker known as the common acute lymphoblastic leukemia antigen (CALLA). Neprilysin/CALLA is highly positive in acute lymphatic leukemia and hematological diseases, and it could be used as a biomarker to indicate the effectiveness of the proposed treatment on lymphopenia in COVID and other diseases.
- Neprilysin Inhibitors
- By blocking the action of Neprilysin, Neprilysin Inhibitors limit the degradation of NPs. This can extend the availability of naturally occurring NPs and enhance their beneficial effects. (REFERENCE 5). Neprilysin Inhibitors also have a negligible inhibitory effect on other metallopeptidase such as NEP2, ECE1, ECE2.
- Beside blocking the NPs degradation, Neprilysin inhibitors have a variety of other effects that are relevant to the treatment of coronavirus infections, as follows:
-
- Blocking or downregulating the expression of ACE2 receptors, which reduces the ports of entry for the virus to infect a cell
- Improving the balance between ACE and ACE2, which helps to mitigate the dysregulation of the RAAS and related cross talk systems (KKS, immune, sympathetic)
- May block or downregulating the collaborator protein TMPRSS2, which is required for the virus to enter and infect the cell
- Downregulating interleukin IL-6, which helps to mitigate the cytokine storm by discouraging the secretion of proteins and factors that contribute to vascular permeability and leakage that are part of the hypotension and pulmonary dysfunction in ARDS
- Neprilysin inhibitors have a number of secondary benefits that help to mitigate the effects of the runaway immune response and cytokine storm:
-
- Reducing inflammation and hyperreactivity in the airway by increasing glucagon
- Mitigating the cytokine storm by downregulating interleukin IL-6, which discourages the secretion of proteins and factors that contribute to the vascular permeability and leakage that are part of the hypotension and pulmonary dysfunction in ARDS
- Protecting the lungs from acute lung injury by increasing oxytocin
- Inhibiting influenza, a virus infection by increasing methionine enkephalin which upregulates the antiviral state in RAW264.7 cells
- Neprilysin promotes the expression of bradykinin receptors. Inhibiting neprilysin with sacubitril will decrease the expression of the bradykinin receptors. and the overall effect of bradykinin.
- Neprilysin plays an alternate role in balancing the Angiotensin's and rebalancing the RAAS, independent on other pathways.
- Possible Side Effects from Neprilysin Inhibitors
- The following side effects were observed in extreme situations in vitro:
-
- At artificially high doses and in the presence of Angiotensin-Converting Enzyme Inhibitors (ACEI), Neprilysin Inhibitors may inhibit the degradation of bradykinins and other inflammatory peptides, resulting in angioedema, bronchoconstriction, and inflammation (REFERENCE 13)
- Inhibiting the degradation of amyloid b peptides, which may predispose the patient to Alzheimer's, age-related macular degeneration, and cerebral amyloid angiopathy. (Observed in vitro)
- Inhibiting the degradation of Bombesin-like peptide, a mitogen, may promote cancer. (Observed in vitro)
- May lead to sensorimotor axonal polyneuropathy
- Existing or Expired Medications That Can Be Used
-
- Sacubitril combined with valsartan (LCZ696. Manufactured and trademarked by Novartis as Entresto™)
- Sacubitril (AHU-377), a prodrug which is a component of sacubitril/valsartan. Sacubitril is a prodrug that is activated to Sacubitrilat (LBQ657) by demethylation via esterase Sacubitrilat is the compound that inhibits the enzyme neprilysin
- Sacubitrilat (LBQ657), the active metabolite of sacubitril.
- RB-101, an enkephalinase inhibitor, used in scientific research.
- UK-414,495
- Omapatrilat (dual inhibitor of Neprilysin and angiotensin-converting enzyme) developed by BMS did not receive FDA approval due to angioedema safety concerns.
- Ecadotril.
- Candoxatril
- Routes of Administration
- The routes of administration of the treatment will depend on the patient's condition, preferences, and state of health. The routes that may be used include the following:
-
- Oral route (PO) in the form of pills, capsules, or tablets, or as a solution or liquid.
- Injection route Intravenous (IV), intramuscular (IM), or subcutaneous (SC)
- Intrathecal
- Transrectal Suppository
- Inhalational route/pulmonary route-Bronchial, Inhalation, or nasal spray
- Sublingual/Buccal route. Sublabial
- Topical route Creams, ointments,
- Transdermal patch,
- Eyedrops
- In the form of long acting, short acting, immediate release, or delayed release.
- Tailoring the Treatment
- The treatment can be tailored to reflect the specific symptoms and complications that each patient experiences.
- For example, the particular affinities of the A-type NP may be included or emphasized in the treatment when the following conditions are present:
-
- Acute Respiratory Distress Syndrome and Pulmonary hypertension
- Cytokine Storm and significant involvement of the immune system
- Renal hypertension
- Electrolyte imbalance
- Overstimulated sympathetic nervous system (in excess)
- Overweight patients
- The B-type NPs may be included or emphasized in the treatment when there is cardiac failure or involvement of the central nervous system and its essential regulatory centers. (and regulatory systems). The C-type NPs may be included or emphasized in the treatment to prevent or mitigate (hypercoagulation and) thromboembolic phenomena.
- Periods and Timing of the Treatment
- The timing of the treatment may also be tailored to reflect the specifics of each patient's condition and situation. For example, if the treatment is intended to be a preventative measure for a patient who was exposed to a known carrier of SARS-COV-2, the recommended treatment would be from 14 to 21 days, or at the incubation period of the virus. For this it may be applicable to use a rectal suppository, to prevent GI shedding and spreading, buccal, or sublingual, nasal spray, inhalation, or to prevent and mitigate the respiratory spreading and the following lung injury and ARDS or as preventing in exposed individual and community.
- For a mild form of the disease, where only cough, fever, myalgia, and fatigue are experienced, treatment for a period of one week, or until the symptoms subsided, would be appropriate.
- In patients with moderate to severe condition, the treatment might continue until a significant improvement is seen and continued until the patient is discharged.
- In critical patients, IV, intrabrachial treatments of 3 to 4 days with high doses may be indicated.
- When there are neurological complications, such as encephalitis and neurological deficits, it may be advisable to use intrathecal route.
-
-
- NP's are increased in the early stage of cardiac failure in Covid 19 disease and favor a recovery, while high NPs in severe patients with late increase correlate with increased death (REFERENCE 19)
- NP's are elevated in early stage of sepsis favor for recovery, compared to a late increase in late stages of the sepsis when there is a high mortality rate.
- NPs are elevated in COVID disease with no explanation elevate among patients with severe respiratory illnesses even in the absence of elevated filling pressures or clinical heart failure.
- The following are examples of how the treatment could be implemented with different combinations of medications, routes of administration, and timing.
- All the following encounter regimes may be extended to lower doses as long as there is a clinical improvement and may extend to higher doses as long as there are no serious side effects and still there is increase in benefit.
- Single NP, Administered Via IV
- In one implementation, the treatment is administered in the form of recombinant BNP (such as Natrecor™ which is manufactured by Janssen) with an initial IV bolus of 2 mcg/kg, followed by a continuous infusion of flow rate of 0.01 mcg/kg/min for up to 96 hours. This may be indicated for patients with heart failure and/or involvement of the Central Nervous System. The dose-limiting side effect of Natrecor™ is severe hypotension. Do not initiate the treatment if systolic blood pressure is less than 110.
- Single NP, Administered Via IV
- In another instance, the treatment is administered in the form of ANP human recombinant, such as Carperitide™ (manufactured by Daiichi Sankyo, Japan) in a low dose such as intravenous 0.02 mcg/kg/min for up to 72 hours.
- Combination of NPs, Administered Via IV
- In yet another implementation, the treatment is a combination of recombinant ANP, BNP, and CNP, administered by IV, with the following doses: ANP with a continuous infusion of 0.02 mcg/kg/min; and BNP with a continuous infusion of flow rate of 0.01 mcg/kg/hr; and CNP with a continuous infusion of 0.001 mcg/kg/min. The medications are administered for up to 96 hours or until the desired clinical effects are achieved. This may be indicated for heart failure and/or thrombosis or microangiopathy.
- Neprilysin Inhibitor (Sacubitril) and ARB (Valsartan), commercially available as Entresto™, Administered Via Tablet
- Another example of the treatment is a combination of sacubitril and valsartan, administered as a tablet twice daily, with increasing doses as tolerated, beginning at 50 mg (24 mg sacubitril/26 mg valsartan) and increasing to 100 mg (49/51 mg) and then to 200 mg (97/103) mg. The treatment is continued until the clinical effects are achieved.
- Even though this invention does not include synergistic drug combinations of different classes, since Entresto™ is the only available drug for NI, we still use it.
- Sacubitril, PO, BID, Administered Via Tablet
- In this example, the treatment is sacubitril administered orally, twice daily, with a dose of 100 mg BID The treatment is continued until the clinical effects are achieved.
- NPs and Sacubitril, Administered Via IV
- In this instance of the invention, the treatment is a combination of NPs (ANP, BNP, CNP) and sacubitril administered as a continuous infusion in a clinically appropriate dose such as a total of 0.01 mcg/kg/min for the NPs and 100 mg BID for the sacubitril.
- ANP, BNP, Sacubitril, Administered Via Intrathecal Injection
- In this instance of the invention, the treatment consists of ANP, BNP, and sacubitril, administered via a single injection into the spinal column (intrathecal). The doses are the lowest doses of to avoid neurotoxicity. This may be indicated for involvement of the Central Nervous System.
- Nasal Spray
- In this instance one can use a saline solution of 0.68-0.9% 9
cc adding Carperitidern 1 cc of 0.01 mcg/cc concentration which will make it a concentration of 0.001 mcg/cc apply at least 3 times a day. - Inhalation Route
- Inhalation route might be very important in preventing lung injury and further ARDS; by preventing the endothelial permeability as well as shedding virus infected ace2.
- For example, one could use a soluble ANP (Carperitide™) In this instance one can use a saline solution of 0.68-0.9% 9
cc adding Carperitidern 1 cc of 0.01 mcg /cc concentration which will make it a concentration of 0.001 mcg/cc in propellant HFA˜134a (1,1,′1,2 tetrafluoroethane) and ethanol. apply at about 3 times a day. - Rectal Route Suppository
- This route may prevent and mitigated gastrointestinal symptoms complication and long-time virus spreading. For example, using cocoa butter or a similar substitute, polyethylene glycol, hydrogels, and glycerinated gelatin as a base and add ANP in the form of Carperitide ,M or powder.
- Single NP
- Natrecor™ (Nesiritide)
- As described in https://www.rxlistcmn/natrecor-drug.htm
- The recommended dose of NATRECOR™ is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min up to 96 hours. Do not initiate NATRECOR™ at a dose that is above the recommended dose. The loading dose may not be appropriate for those with low systolic blood pressure (SBP)<110 mm Hg or for patient.
- Carperitide™
- Manufactured by Daiichi Sankyo, Japan also known as Anaritide
- In a low dose such as slow rate of Intravenous 0.01-0.02 mcg/kg/min for up to 72 hours. Carperitide™ or A anaritide (Auriculin™, or human atrial natriuretic peptide, amino acid residues 102 to 126; Scios, Mountain View, Calif.) compares favorably to Nesiritide™ in several ways; it has a shorter half-life (2 minutes), does not mandate bolus infusion, and is used mostly as a single.
- Glyco-Modified Atrial Natriuretic Peptide Derivatives
- Synthesized Using Chemo-enzymatic Synthesis Approaches
- This version of ANP has an extended the half-life of 14.9 d but not available as yet. (REFERENCE 17)
- CDuNP Cenderitide Subcutaneous
- Daily subcutaneous infusion of CD-NP at 10-30 ng/kg/day over period of 5 to 30 days (REFERENCE 17)
- CD-NP Cenderitide Patch
- (REFERENCE 17) sustained release 12-84 mg/ml (for 0-6 hours) or 1-6 mg/ml (for 1-30 days). film (1 cm 61 cm 60.004 cm) with a release of 1-6 ng/kg/day (between 1 to 30 days)
- Ularitide
- 15 ng/kg body weight continuous infusion for 3 days, which will address mostly kidney and heart failure
- VNP
- Single bolus of 50 μg/kg
- ANX 042
- IV—(still investigational)
- Subcutaneous (SQ) MANP (ZD100)
- which is highly resistant to degradation by NEP, as well as it seems the best-in-class pGC-A activator, once a day subcutaneous administration for 3 days
- Combination of NPs
- A combination of Nesiritidern but half the dose a single administration re a bolus of an IV bolus of 1 mcg/kg (to omit if blood pressure is <“110) followed by a continuous infusion of 0.005 mcg/kg/min up to 96 hours, and Carperitide™ (manufactured by Daiichi Sankyo, Japan) (Anaritide) in a low dose such as slow rate of Intravenous 0.005-0.01 mcg/kg/min tor up to 72 hours,
- Neprilysin Inhibitor (Sacubitril) and ARB (Valsartan)
- Sacubitril/Valsartan (LCZ696); available as Entresto by Novartis. Sacubitril (24 mg, 49 mg, or 97 mg) and valsartan (26 mg, 51 mg, or 103 mg). The valsartan component in this combination has a higher bioavailability as compared to regular valsartan tablets; therefore, valsartan 26 mg, 51 mg, and 103 mg in the brand-name combination are equivalent to valsartan 40 mg, 80 mg, and 160 mg in other formulations, respectively. To be given from the exposure for at least a month.
- NPs and Sacubitril
- NP as described in single NP above such as 3 days of the above one of the NP with the doses and preparation as described for a single dose. Carperitide™ 0.01-0.02 mcg/kg/min for up to 72 hours or Nesiritide™ continuous infusion of 0.01 mcg/f . . . ; g/min up to 96 hours it may with halt the dose of the first bolus, re IV bolus of 1 mcg/kg) and Sacubitril (24 mg, 49 mg, or 97 mg). It may be useful to start Sacubitril before or together with the NP.
- ANP, BNP, Sacubitril
- In this combination, will use both ANP and BNP as a combination of Nesiritide™ but half the dose a single administration re a bolus of an IV bolus of 1 mcg/kg (to omit if blood pressure is <110) followed by a continuous infusion of 0.005 mcg/kg/min up to 96 hours and Carperitide™ (manufactured by Daiichi Sankyo, Japan) (Anaritide) in a low dose such as slow rate of Intravenous 0.005-0.0i mcg/kg/min for up to 72 hours and Sacubitril (24 mg, 49 mg, or 97 mg). It may be useful to start Sacubitril before or together with the NP.
- Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the embodiments. Therefore, it must be understood that the illustrated embodiments have been set forth only for the purposes of example and that it should not be taken as limiting the embodiments as defined by the following embodiments and its various embodiments.
- Therefore, it must be understood that the illustrated embodiments have been set forth only for the purposes of example and that it should not be taken as limiting the embodiments as defined by the following claims. For example, notwithstanding the fact that the elements of a claim are set forth below in a certain combination, it must be expressly understood that the embodiments include other combinations of fewer, more or different elements, which are illustrated embodiments of the above even when not initially claimed in such combinations. A teaching that two elements are combined in a claimed combination is further to be understood as also allowing for a claimed combination in which the two elements are not combined with each other, but may be used alone or combined in other combinations. The excision of any illustrated embodiment of the element of the embodiments is explicitly contemplated as within the scope of the embodiments.
- The words used in this specification to describe the various embodiments are to be understood not only in the sense of their commonly defined meanings, but to include by special definition in this specification structure, material or acts beyond the scope of the commonly defined meanings. Thus, if an element can be understood in the context of this specification as including more than one meaning, then its use in a claim must be understood as being generic to all possible meanings supported by the specification and by the word itself.
- The definitions of the words or elements of the following claims are, therefore, defined in this specification to include not only the combination of elements which are literally set forth, but all equivalent structure, material or acts for performing substantially the same function in substantially the same way to obtain substantially the same result. In this sense, it is therefore contemplated that an equivalent substitution of two or more elements may be made for any one of the elements in the claims below or that a single element may be substituted for two or more elements in a claim. Although elements may be described above as acting in certain combinations and even initially claimed as such, it is to be expressly understood that one or more elements from a claimed combination can in some cases be excised from the combination and that the claimed combination may be directed to a sub-combination or variation of a sub-combination.
- Insubstantial changes from the claimed subject matter as viewed by a person with ordinary skill in the art, now known or later devised, are expressly contemplated as being equivalent within the scope of the claims. Therefore, obvious substitutions now or later known to one with ordinary skill in the art are defined to be within the scope of the defined elements.
- The claims are thus to be understood to include what is specifically illustrated and described above, what is conceptually equivalent, what can be obviously substituted and also what essentially incorporates the essential idea of the embodiment.
-
- 1. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Chhinder P. Sodhi et al. Am J Physiol Lung Cell Mal Physiol 314: L17-L31, 2018. journals.physiology.org/doi/full/10.1152/ajplung.00498.2016
- 2. Takeda, H., Katagata, Y., Hozumi, Y., Kondo, S., 2004. Effects of Angiotensin II Receptor Signaling during Skin Wound Healing. The American Journal of Pathology 165, 1653-1662 . . . doi:10.1016/50002-9440(10)63422-0 IT
- 3. Natriuretic peptides in cardiometabolic regulation and disease. Zais, N. E. et al. Nat. Rev. Cardiol. 11, 403-412 (2014); published online 13 May 2014; doi:10.1038/nrcardio.2014.64
- 4. The role of atrial natriuretic peptide in the immune system Peptides Volume 26, Issue 6, June 2005, Pages 1086-1094 www.sciencedirect.com/science/article/abs/pii/S0196978105000938
- 5. Long-term neprilysin inhibition—implications for ARNIs Nature Reviews Cardiology volume 14, pages171-186(2017) www.nature.com/articles/nrcardio.2016.200
- 6. Santhekadur, P. K., Kumar, D. P., Seneshaw, M., Mirshahi, F., Sanyal, A. J., 2017. The multifaceted role of natriuretic peptides in metabolic syndrome. Biomedicine & Pharmacotherapy 92, 826-835 . . . doi:10.1016/j.biopha.2017.05.136
- 7. Mahajan, K., Negi, P., 2020, The roe of natriuretic peptide estimation in severe COVID-19, Monaldi Archives for Chest Disease . . . doi:10.4081/monaldi.2020.1316 www.sciencedirect.com/science/article/abs/pii/S0891584916304002,
- 8. Vesely, D. L., 2013. Cardiac hormones for the treatment of cancer. Endocrine-Related Cancer 20, R113-R125 . . . doi:10.1530/erc-13-0054
- 9. Effect of Short-Term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Physiol. Res. 59: 625-628, 2010. www.biomed.cas.cz/physiolres/pdf/59/59_625.pdf
- 10. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain Rongrong Chen, Keer Wang, Jie Yu, Derek Howard, Leon French, Zhong Chen, Chengping Wen, View ORCID ProfileZhenghao Xu doi.org/10.1101/2020.04.07.030650
- 11. The Emerging Role of Atrial Natriuretic Peptide in Psychiatry Curr Med Chem 2020 Feb. 18. pubmed.ncbi.nlm.nih.gov/32072888/12.
- 12. Perlot, T., Penninger, J. M., 2013. ACE2—From the renin-angiotensin system to gut microbiota and malnutrition. Microbes and Infection 15, 866-873 . . . doi:10.1016/j.micinf.2013.08.003
- 13. Neprilysin Inhibitors and Bradykinin. Frontiers in Medicine. Campbell, D. J., 2018. doi:10.3389/fmed.2018.00257 www.frontiersin.org/articles/10.3389/fmed.2018.00257/full
- 14. Alessandro Sette, Shane Crotty, Adaptive immunity to SARS-CoV-2 and COVID 19, Cell, Volume 184,
Issue 4,2021, Pages 861-880,ISSN 0092-8674,https://doi.org/10.1016/j.cell.2021.01.007. (https://www.sciencedirect.com/science/article/pii/S0092867 421000076) - 15. Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. Journal of the American Heart Association. Reddy, Y. N. V., Iyer, S. R., Scott, C. G., Rodeheffer, R. J., Bailey, K., Jenkins, G., Batzler, A., Redfield, M. M., Burnett, J. C., Pereira, N. L., 2019. doi:10.1161/jaha.119.012943pubmed.ncbi.nlm.nih.gov/31345101/
- 16. Is there an impact of the COVID-19 pandemic on male fertility? The ACE2 connection Johnny S. Younis, Zaid Abassi, and Karl Skorecki American Journal of Physiology-Endocrinology and Metabolism 2020 318:6, E878-E880)
- 17. Laura M. G. Meems, John C. Burnett, Innovative Therapeutics: Designer Natriuretic Peptides, JACC: Basic to Translational Science,
Volume 1,Issue 7, 2016, Pages 557-567, ISSN 2452-302X, https://doi.org/10.1016/j.jacbts.2016.10.001. - 18. Recombinant human brain natriuretic peptide ameliorates trauma-induced acute lung injury via inhibiting JAK/STAT signaling pathway in rats. Song, Zhi et al. Journal of Trauma and Acute Care Surgery: May 2015—Volume 78—Issue 5—p 980-987. doi: 10.1097/TA.0000000000000602
- 19. Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., Lu, Z., 2020. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology 5, 811 . . . doi:10.1001/jamacardio.2020.1017
- 20. Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. Journal of the American College of Cardiology. Lisy, O., Huntley, B. K., Mccormick, D. J., Kurlansky, P. A., Burnett, J. C., 2008. doi:10.1016/j.jacc.2008.02.077
- 21. Chen B-Y, Chen J-K, Zhu M-Z, Zhang D-L, Sun J-S, et al. (2011) AC-NP: A Novel Chimeric Peptide with Natriuretic and Vasorelaxing Actions. PLoS ONE 6(5):e20477. doi:10.1371 /journal.pone.0020477)
- 22. Mtps://covid-·19trad.;;er.miikeninstitute.org/#tmatment_antibodies
- 23. Acanfora, D., Ciccone, M. M., Scicchitano, P., Acanfora, C., Casucci, G., 2020. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. European Heart Journal—Cardiovascular Pharmacotherapy 6, 135-136 . . . doi:10.1093/ehjcvp/pvaa028
- 24. Currie, M. G., Zimmer, D. P., Halushka, P. V., 2020. An impaired natriuretic peptide hormone system may play a role in COVID-19 severity in vulnerable populations.
FASEB BioAdvances 2, 596-599 . . . doi:10.1096/fba.2020-00042
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/866,530 US20220362344A1 (en) | 2020-04-07 | 2022-07-17 | Treatment for sars-cov-2 and other coronaviruses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063006580P | 2020-04-07 | 2020-04-07 | |
US202063050003P | 2020-07-09 | 2020-07-09 | |
US17/221,009 US11419917B2 (en) | 2020-04-07 | 2021-04-02 | Treatment for SARS-CoV-2 and other coronaviruses |
US17/866,530 US20220362344A1 (en) | 2020-04-07 | 2022-07-17 | Treatment for sars-cov-2 and other coronaviruses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/221,009 Division US11419917B2 (en) | 2020-04-07 | 2021-04-02 | Treatment for SARS-CoV-2 and other coronaviruses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220362344A1 true US20220362344A1 (en) | 2022-11-17 |
Family
ID=77921024
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/221,009 Active US11419917B2 (en) | 2020-04-07 | 2021-04-02 | Treatment for SARS-CoV-2 and other coronaviruses |
US17/866,530 Pending US20220362344A1 (en) | 2020-04-07 | 2022-07-17 | Treatment for sars-cov-2 and other coronaviruses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/221,009 Active US11419917B2 (en) | 2020-04-07 | 2021-04-02 | Treatment for SARS-CoV-2 and other coronaviruses |
Country Status (1)
Country | Link |
---|---|
US (2) | US11419917B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220143123A1 (en) * | 2020-07-13 | 2022-05-12 | Therapeutic Solutions International, Inc. | Prevention of Pathological Coagulation in COVID-19 and other Inflammatory Conditions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
EP2457581A1 (en) * | 2009-07-23 | 2012-05-30 | Igisu Co., Ltd. | Composition for external preparation for skin |
US20140294851A1 (en) * | 2013-04-01 | 2014-10-02 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
US9884807B2 (en) * | 2012-06-08 | 2018-02-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339210C (en) | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
KR20100059859A (en) | 2007-09-11 | 2010-06-04 | 몬도바이오테크 래보래토리즈 아게 | Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent |
US8883144B2 (en) | 2010-09-02 | 2014-11-11 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of pulmonary vascular remodeling with neprilysin |
US9314507B2 (en) | 2010-10-29 | 2016-04-19 | Capricor Therapeutics, Inc. | Methods of treatment of heart failure with natriuretic peptides |
WO2012115772A2 (en) | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
WO2013033675A1 (en) | 2011-09-02 | 2013-03-07 | Medtronic, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
US20150045301A1 (en) | 2011-12-16 | 2015-02-12 | Kalos Therapeutics, Inc. | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases |
CN103142490B (en) | 2012-11-28 | 2014-08-06 | 深圳市健元医药科技有限公司 | Nesiritide acetate sustained-release microsphere preparation and preparation method thereof |
CN103204922A (en) | 2013-03-22 | 2013-07-17 | 深圳翰宇药业股份有限公司 | Method for preparing nesiritide |
KR102569599B1 (en) | 2015-08-28 | 2023-08-21 | 헤테로 랩스 엘티디. | Process for the preparation of dual-acting angiotensin receptor-neprilysin inhibitor compounds |
-
2021
- 2021-04-02 US US17/221,009 patent/US11419917B2/en active Active
-
2022
- 2022-07-17 US US17/866,530 patent/US20220362344A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
EP2457581A1 (en) * | 2009-07-23 | 2012-05-30 | Igisu Co., Ltd. | Composition for external preparation for skin |
US9884807B2 (en) * | 2012-06-08 | 2018-02-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US20140294851A1 (en) * | 2013-04-01 | 2014-10-02 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US20210308224A1 (en) | 2021-10-07 |
US11419917B2 (en) | 2022-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Samuel et al. | Anti‐fibrotic actions of relaxin | |
AU2018202504B2 (en) | Use of long-acting GLP-1 peptides | |
JP5161412B2 (en) | Methods of using GLP-1 and GLP-2 peptides | |
US8455435B2 (en) | Remedies for ischemia | |
Kim et al. | The nonglycemic actions of dipeptidyl peptidase-4 inhibitors | |
RU2387454C2 (en) | Compositions and methods of treating cardiovascular disease | |
Choi et al. | Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation | |
Takahashi et al. | Angiotensin II and tumor necrosis factor-α synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-κB, p38, and reactive oxygen species | |
Liu et al. | Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction | |
US20220362344A1 (en) | Treatment for sars-cov-2 and other coronaviruses | |
KR101989201B1 (en) | Anti-inflammatory compositions | |
MX2012002175A (en) | Therapeutic agent for rhinitis. | |
Mostafa | Non-sexual implications of phosphodiesterase type 5 inhibitors | |
Jankowski et al. | Oxytocin in the heart regeneration | |
Lin et al. | Neuregulin‑1, a microvascular endothelial‑derived protein, protects against myocardial ischemia‑reperfusion injury | |
EP2098244A1 (en) | Pharmaceutical composition for the treatment of myocardial infarction | |
Xue et al. | Low-dose decitabine assists human umbilical cord-derived mesenchymal stem cells in protecting β cells via the modulation of the macrophage phenotype in type 2 diabetic mice | |
DK2007416T3 (en) | PARATYROIDEAHORMON (PTH) TO USE IN THE TREATMENT OF ICE CREAM | |
Burian et al. | Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms | |
US20180008675A1 (en) | Use of urodilating for preparing a medicament for treatment of cardiovascular, renal, pulmonary, and neuronal syndromes while avoiding a rebound | |
CN113164549A (en) | Pharmaceutical composition for preventing or treating obesity, fatty liver or steatohepatitis comprising inhibitory peptide against Fas signaling | |
KR101324647B1 (en) | Composition for treating or preventing of multiple sclerosis and screening thereof | |
US8507446B2 (en) | Use of PEDF-derived polypeptides for treating liver cirrhosis | |
Kwok et al. | DPP-IV inhibitors: Beyond glycaemic control? | |
KR20100005120A (en) | Method of preventing or treating body weight disorders by employing clusterin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |